  Clinical Study Protocol 
    BTCRC-ESO14-012  
09OCT2019  Confidential  Page 1 of 79 
 
Protocol Title 
A Phase II Study Evaluating Safe ty and Efficacy of Durvalumab ( MEDI4736) 
Following Multi-Modality Therapy in  Esophageal Cancer: Big Ten Cancer Research 
Consortium BTCRC-ESO14-012  
 
 
Sponsor-Investigator 
Shadia Jalal, MD 
Indiana University Melvin a nd Bren Simon Cancer Center 
  
Co-Investigators  
Hirva Mamdani, MD 
Nasser Hanna, MD 
Kenneth Kesler, MD 
Sunil Badve, MD 
Milan Radovich, PhD 
  
Statistician 
Susan Perkins, PhD 
  
Trial Supported by  
MedImmune, LLC, a wholly owned s ubsidiary of AstraZeneca PLC 
(ESR-14-10654)  
 
Trial Management by 
Big Ten CRC Administrative Headqu arters at Hoosier Cancer Resea rch Network 
500 N. Meridian, Suite 100 
Indianapolis, IN 46204 
 
Investigational New Drug (IND) Application #   
129416 
   
Initial Protocol Version Date: 23DEC2015  
 Amendment Version Date: 15MAR2017 19FEB2018  07DEC2018 (IU only) 24JAN2019 09OCT2019 (current) 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012  
09OCT2019  Confidential  Page 2 of 79 PROTOCOL SIGNATURE PAGE 
 
A Phase II Study Evaluating Safety and Efficacy of Durvalumab ( MEDI4736) Following Multi-
Modality Therapy in E sophageal Cancer:  
Big Ten Cancer Research C onsortium BTCRC-ESO14-012 
 
VERSION DATE:  09OCT2019 
I confirm I have read this pr otocol, I understand it, and I wil l work according to this protocol and 
to the ethical principles stated in the latest version of the D eclaration of Helsinki, the applicable 
guidelines for good clinical pract ices, or the applicable laws and regulations of t he country of the 
study site for which I am responsib le, whichever provides the g reater protection of the individual. 
I will accept the monitor’s overseeing of the study. I will pro mptly submit the protocol to 
applicable ethical review board(s).          ____________________________________ ________________________  S i g n a t u r e  o f  S i t e  I n v e s t i g a t o r              Date 
  ____________________________________  Investigator Name (printed)   ____________________________________  Investigator Title   ____________________________________  Name of Facility   ____________________________________  Location of Facility (City and State)  
____________________________________  Not Submitting to IRB 
 Expected IRB Approval Date  
PLEASE COMPLETE AND EM AIL TO BIG TEN CRC  
ADMINISTRATIVE HEADQUARTERS  Instructions to the i nvestigator:  Please SIGN  and DATE  this signature page.  
PRINT  your name and title, the name a nd location of the facility in which the 
study will be conducted, and the e xpected IRB approval date.  S can and email 
the completed form to BRTCRC Ad ministrative H eadquarters and ke ep a 
record for your files. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012  
09OCT2019  Confidential  Page 3 of 79 STUDY SYNOPSIS  
 
TITLE A Phase II Study Evaluating Safety and Efficacy of Durvalumab 
(MEDI4736) Following Multi-Modality Therapy in Esophageal Cance
r 
SHORT TITLE A Phase II Study of Durvalumab (MEDI4736) in Esophageal Cancer 
PHASE  II 
OBJECTIVES Primary Objective:  
 To determine if postoperative ad juvant therapy with durvalumab 
improves 1 year relapse free su rvival (RFS) compared to histori cal rates 
in patients with persistent es ophageal cancer following neoadju vant 
chemoradiotherapy and esophagectomy  
 Secondary Objectives:   
 To assess the toxicity and tol erability of durvalumab following  
trimodality therapy in patient s with esophageal cancer.  
 Correlative Objectives:  
 To assess changes in PD-L1 expr ession with chemoradiotherapy in  
esophageal cancer.  
 To analyze possible predictive  biomarkers of 1 year RFS includi ng PD-
L1 expression (at diagnosis and in residual disease) in tumor c ells and 
tumor infiltrating lymphocytes (by histology and gene expressio n 
analysis – by pathway analysis a nd CIBERSORT), both within the 
tumor and in surrounding connective tissue. 
 To assess the Immunoscore (ba sed on numeration of lymphocyte 
populations - CD3/CD45RO, CD3/C D8, CD8/CD45RO) – within the 
center and invasive margins of t he tumor – and correlate with 1  year 
RFS. 
 To analyze the correlation betw een changes in circulating tumor  cell 
numbers in response to PD-L 1 inhibition and 1 year RFS in patie nts 
with residual esopha geal cance r. 
OUTCOME 
MEASURES  Primary: Relapse free su rvival (RFS) at 1 year 
 Secondary: Incidence and sever ity of adverse events overall and  related 
to the study drug.  
 Explorator y outcomes as above.
STUDY DESIGN Phase II, open-label, single arm , single-stage study. A total o f 23 evaluable 
patients will be enrolled (26 total to account for 10% unevalua ble). If total 
number of patients free of disease relapse at 1 year is less th an or equal to 15, 
the drug would not be considered f or further study in this sett ing. To improve 
accuracy for estimating the prima ry endpoint (1 year RFS) with a 95% 
confidence interval, an additional 11-16 patients beyond the in itial planned 
23 evaluable will be enrolled for a target of 34-39 enrolled to  have at least 34 
patients evaluable for 1 year RFS.  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012  
09OCT2019  Confidential  Page 4 of 79 After six patients are treate d with at least one dose of study drug, they will 
be observed for a minimum of  60 days. During the 60-day observa tion 
period, further accrual will be halted to evaluate "unacceptabl e toxicities 
warranting early closure of the trial" defined as:  
1) Any definitive durvalumab-relate d death. A durvalumab-related d eath 
will be continuously monitored throughout the trial and the tri al will be 
suspended for re-evaluation whene ver such an event is confirmed . 
2) Any unexpected and previously unre ported grade 4 toxicities def initely 
related to durvalumab. 
 If such events are observed in one subject, the DSMB will discu ss and 
provide recommendations to the spon sor-investigator. If such ev ents are 
observed in two or more subjects, t he trial will be suspended f or re-
evaluation.  Pneumonitis of grade 3 and 4 will be continuously monitored. An  overall 
rate of 20% or above would be cons idered unacceptable. If the p robability 
of the grade 3/4 pneumonitis rate being less than 20% drops bel ow 0.1, the 
trial will be suspende d for re-evaluation.
ELIGIBILITY 
CRITERIA  Inclusion Criteria: 
- Esophageal cancer with persistent  residual diseas e in the surgi cal 
sample following neoadjuvant conc urrent chemoradiotherapy 
(carboplatin and paclitaxel or c isplatin and 5-FU) followed by surgical 
resection.  
- Must have had R0 resection (define d as resection with negative 
margins) 
- Minimum of 1 month and maximum  of 3 months from surgical 
resection with no evidence of dis ease recurrence at the time of  
enrollment 
- ECOG Performance status 0-1 
- Adequate bone marrow, r enal and hepatic function 
- Must have adequately recovered from chemoradiation and surgery 
Exclusion Criteria: 
- Prior therapy with a PD-1, PD-L 1, or CTLA-4 inhibitor or cancer -
specific vaccine therapy 
- Patients with R1 resection (define d as positive ma rgins after r esection) 
or R2 resection (defined as presen ce of macroscop ic residual di sease 
after resection) 
- Evidence of active autoimmune disease requiring systemic treatm ent 
within preceding 3 months or a docum ented history of clinically  severe 
autoimmune disease, or a syndr ome that requires ongoing use of 
systemic steroids or immunosuppre ssive agents. Exceptions to th is rule 
include vitiligo, resolved chil dhood asthma/atopy, requirement of 
intermittent bronchodilators or  local steroid injections, hypot hyroidism 
stable on hormone replacemen t, Sjogren’s syndrome. 
- Presence of interstitial lung di sease or history of pneumonitis  requiring 
treatment with corticosteroids
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012  
09OCT2019  Confidential  Page 5 of 79 - Patients with diagnosis of imm unodeficiency or those receiving chronic 
systemic corticosteroid therapy or  other immunosuppressive ther apy 
(except inhaled stero ids) within 28 days of the first dose of s tudy drug 
- History of psychiatric illness/so cial situations that would lim it 
compliance with study requirements. 
- Clinically significan t infections as judge d by the treating inv estigator. 
Clinically significant is defined as an active infection requir ing IV 
antibiotics 
- Known HIV infection or chr onic hepatitis B or C. 
STATISTICAL 
CONSIDERATIONS  Null Hypothesis: 1 year RFS with pos toperative adjuvant durvalu mab 
therapy in patients with persi stent esophageal cancer following  neoadjuvant 
chemoradiotherapy and esophagectomy is 50% or less. Alternative Hypothesi s: 1 year RFS with postoperative adjuvant 
durvalumab therapy i n patients with persistent esophageal cance r following 
neoadjuvant chemoradiotherapy a nd esophagectomy is 75% or great er. 
Acceptable Type I (alpha) error: 5% 
Acceptable Type II (beta) error: 20% 
Power: 80% 
Phase II, open label, sin gle arm, sin gle-sta ge stud y.  
TOTAL  NUMBER OF SUBJECTS  Total n=39, 34 efficacy evaluable and allowing for up to 5 unev aluable. 
Subjects who receive less than 6 m onths of durvalumab for reaso ns 
unrelated to disease progression or toxicity will be replaced. 
ESTIMATED ENROLLMENT PERIOD Estimated 18 months 
ESTIMATED 
STUDY DURATION  Estimated 39 months  
 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012  
09OCT2019  Confidential  Page 6 of 79 INDEX  
 
SECTION                                                                                                                 PAGE 
 
SCHEMA  .............................................................. ............................................................... ............. 8  
1.  BACKGROUND & RATIONALE  .............................................................. .................... 9  
2.  OBJECTIVES, ENDPOINTS A ND OUTCOME MEASURES  ................................. 15  
2.1.  Objectives  .............................................................. ........................................................... 15  
2.2.  Endpoints  .............................................................. ........................................................... 16  
2.3.  Outcome Measures  .............................................................. ............................................ 16  
3.  ELIGIBILITY CRITERIA  .............................................................. .............................. 17  
3.1.  Inclusion Criteria  .............................................................. .............................................. 17  
3.2.  Exclusion Criteria  .............................................................. ............................................. 18  
4.  SUBJECT REGISTRATION  .............................................................. ........................... 19  
5.  TREATMENT PLAN  .............................................................. ....................................... 20  
5.1.  Pre-medication  .............................................................. ................................................... 20  
5.2.  Drug Administration  .............................................................. ......................................... 20  
5.3.  Supportive Care:  .............................................................. ............................................... 20  
5.4.  Concurrent Therapy  .............................................................. ......................................... 20  
5.5.  Restrictions during the study  .............................................................. ........................... 21  
6.  DOSE MODIFICATIONS  .............................................................. ............................... 22  
6.1.  Dose Modifications  .............................................................. ............................................ 22  
7.  STUDY CALENDAR & EVALUATIONS  .............................................................. ..... 50 
7.1.  Screening  .............................................................. ............................................................ 52  
7.2.  On Treatment  .............................................................. .................................................... 52  
7.3.  Protocol therapy discontinuation  .............................................................. ..................... 54  
7.4.  Safety Follow-up: 30 days (±7 days)  after last dose of protocol  therapy  ................... 54  
7.5.  At Recurrence:  .............................................................. ................................................... 55  
7.6.  Follow-up ............................................................... ........................................................... 55  
8.  CRITERIA FOR DISEASE EVALUATION  .............................................................. . 55 
9.  BIOLOGICAL CORRELATIVES  .............................................................. .................. 57  
10.  DRUG INFORMATION  .............................................................. .................................. 59  
10.1. Drug Names:  .............................................................. ...................................................... 59  
10.2. Drug Class: ............................................................... ........................................................ 59  
10.3. Formulation, Packaging and Storage  .............................................................. .............. 59  
10.4. Availability and Distribution ............................................................... ........................... 59  
10.5. Preparation  .............................................................. ........................................................ 60  
10.6. Administration  .............................................................. ................................................... 60  
10.7. Precautions  .............................................................. ......................................................... 60  
10.8. Side Effects  .............................................................. ......................................................... 60  
11.  ADVERSE EVENTS  .............................................................. ......................................... 61  
11.1. Definitions  .............................................................. .......................................................... 61  
11.2. Reporting ............................................................... ........................................................... 65  
11.3. IND Safety Reports Unrelated to This Trial  .............................................................. ... 68 
12.  STATISTICAL CONSIDERATIONS  .............................................................. ............ 68  
12.1. General Considerations  .............................................................. .................................... 68  
12.2. Study Design  .............................................................. ...................................................... 69  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012  
09OCT2019  Confidential  Page 7 of 79 12.3. Definition of Primary Endpoint  .............................................................. ....................... 69  
12.4. Definitions of Secondary Endpoints  .............................................................. ................ 69  
12.5. Definitions of Correlative Endpoints  .............................................................. ............... 69  
12.6. Sample Size/Accrual/Study D uration/Replacement Rules  .......................................... 69  
12.7. Criteria for Stopping the Study  .............................................................. ....................... 70  
12.8. Analysis Datasets  .............................................................. ............................................... 70  
12.9. Subject Characteristics and sign ificant protocol violations  ........................................ 70  
12.10. Concomitant Medication  .............................................................. .................................. 70  
12.11. Disposition  .............................................................. .......................................................... 70  
12.12. Analysis Plan for Primary Objectives/Aims  .............................................................. ... 71 
12.13. Analysis Plan for Secondary Objectives/Aims  ..............................................................  7 1 
12.14. Analysis Plan for Correlative/Exploratory Objectives  ................................................ 71  
13.  TRIAL MANAGEMENT  .............................................................. ................................. 71  
13.1  Data and Safety Monitoring Plan (DSMP)  .............................................................. ..... 71 
13.2  Data Quality Oversight Activities  .............................................................. .................... 73  
13.3  Compliance with Trial Registration and Results Posting Requirem ents ................... 73  
14.  DATA HANDLING AND RECORD KEEPING  ......................................................... 74  
14.1  Case Report Forms and Submission  .............................................................. ................ 74  
14.2  Record Retention  .............................................................. ............................................... 74  
14.3  Confidentiality  .............................................................. ................................................... 74  
14.4  Changes to the Protocol and Informed Consent  .......................................................... 75  
15  ETHICS  .............................................................. .............................................................. 75 
15.1  Ethics Review  .............................................................. ..................................................... 75  
15.2  Ethical Conduct of the Study  .............................................................. ........................... 76  
15.3  Informed Consent Process  .............................................................. ................................ 76  
16  REFERENCES  .............................................................. .................................................. 77  
 
09OCT2019  Confidential  Page 8 of 79 
SCHEMA 
 
A Phase II Study Evaluating Safety and Efficacy of Durvalumab ( MEDI4736) Following  
Multi-modality Therapy in  Esophageal Cancer:  
Big Ten Cancer Research Consortium BTCRC-ESO14-012 
                    
 
                  
Durvalumab 1500 mg 
Every 4 weeks  
Up to 12 months (13 doses) 
No disease 
recurrence 
Disease Assessment every 3 months  
Significant toxicity or 
non-PD discontinuation 
Continue treatment up 
to 12 months (13 doses) 
Discontinue 
treatment 
Patients with locally advanced e sophageal cancer without distan t metastasis who have received 
neoadjuvant concurrent chemora diation followed by surgery and h ave persistent residual 
disease in the surgical samp le (esophagus or lymph node or both ), including patients with 
marked (<10% residual tumor), m oderate (10-50% residual tumor) or no definite response 
(>50% residual tumor).  
Follow for relapse free 
survival for 1 year after 
treatment discontinuation. 
Disease 
recurrence  
Discontinue 
treatment 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 9 of 79 1. BACKGROUND & RATIONALE 
 1.1 General Background: 
Esophageal cancer has b een recently described as ‘the silent ep idemic’ because of its rapidly rising 
incidence. It is the 6
th leading cause of cancer related mortality in men in the United  States (1). 
Approximately 16,980 new cases a nd 15,590 deaths are estimated to occur from esophageal cancer 
in U.S. in 2015, with a 5- year survival rate of 17.9% (2). Mul tiple factors contribute to the poor 
prognosis associated with esophageal cancer. These include a) t he advanced stage at the time of 
diagnosis b) the complex biology of the disease with large muta tional burden, and c) resistance to 
currently available therapies (3). Two-thirds of the patients w ith esophageal cancer have locally 
advanced disease. A standard of care for fit patients with loca lly advanced esophageal cancer is tri-
modality therapy with concurrent  platinum-based chemotherapy an d ionizing radiation followed by 
surgical resection. With this approach, only about 29% of the p atients achieve a complete pathologic 
response (4). The majority of patients with persistent residual  disease noted on surgical specimen 
will recur leading to a poor prognosis with median survival of 12 months. No post-operative therapy 
has been shown to improve outcomes in this patient population. With its grim prognosis, there is a 
pressing need for novel agents in the treatment of esophageal c ancer that can decrease the risk of 
relapse following tri -modality therapy. 
 Chemotherapy agents with activity in locally advanced esophagea l cancer are limited to 5 classes 
of agents. These include taxanes (docetaxel or paclitaxel), flu oropyrimidines (capecitabine or 5-
FU), platinums (oxaliplatin, car boplatin, cisplatin), topoisome rase I inhibitors (irinotecan) and 
anthracyclines (epirubicin). Sta ndard chemotherapy regimen in c ombination with ionizing radiation 
for the treatment of locally a dvanced esophageal cancer is eith er weekly carboplatin and paclitaxel 
or cisplatin and 5-FU (4, 5). Outcomes with these regimens are comparable. There is currently no 
proven role for adjuvant chemoth erapy in esophageal cancer pati ents following tri-modality therapy. 
 The importance of an intact immune surveillance in controlling outgrowth of neoplastic processes 
has been known for decades (6). Accumulating evidence shows a c orrelation between tumor-
infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in various malignancies (7-
13). In particular, the presence of CD8+ T-cells and the ratio of CD8+ effector T-cells / FoxP3+ 
regulatory T-cells seems to co rrelate with improved prognosis a nd long-term survival in many solid 
tumors (14). Similar correlati on has been found in esophageal s quamous cell carcinoma as well (15). 
The programmed cell death protei n 1 (PD-1) receptor-ligand inte raction is a major pathway hijacked 
by tumors to suppress host immune  response to the tumor. The no rmal function of PD-1, expressed 
on the cell surface of activated T- cells under physiologic con ditions, is to down-modulate unwanted 
or excessive immune responses esp ecially in peripheral tissues,  including autoimmune reactions. 
PD-1 (encoded by the gene Pdcd1) is an Ig superfamily member re lated to CD28 and CTLA-4 which 
has been shown to negatively re gulate antigen receptor signalin g upon engagement of its ligands 
(PD-L1 and/or PD-L2) (16). PD-1 and family members are type I t ransmembrane glycoproteins 
containing an Ig Variable-type ( V-type) domain responsible for ligand binding and a cytoplasmic 
tail which is responsible for the binding of signaling molecule s. The cytoplasmic tail of PD-1 
contains 2 tyrosine-based signaling motifs, an immunoreceptor t yrosine-based in hibition motif 
(ITIM) and an immune-receptor tyro sine- based switch motif (ITS M). Following T-cell stimulation, 
PD-1 recruits the tyrosine phosphatases SHP-1 and SHP-2 to
 the ITSM motif within its cytoplasmic 
tail, leading to the dephosphor ylation of effector molecules su ch as CD3ζ, PKCθ and ZAP70 which 
are involved in the CD3 T-cell si gnaling cascade (16-19). The m echanism by which PD-1 down 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 10 of 79 modulates T-cell responses is si milar to, but distinct from tha t of CTLA-4 as both molecules regulate 
an overlapping set of signaling proteins. PD-1 was shown to be expressed on activated lymphocytes 
including peripheral CD4+ and CD8+ T-cells, B-cells, T regs and  Natural Killer cells (20). The 
ligands for PD-1 (PD-L1 and PD-L 2) are constitutively expressed  or can be induced i n a variety of 
cell types, including non-hematopoietic tissues as well as in v arious tumors. PD-L1 is expressed at 
low levels on various non-hemat opoietic tissues, most notably o n vascular endothelium, whereas 
PD-L2 is only detectably expre ssed on antigen-presenting cells found in lymphoid tissue or chronic 
inflammatory environments. PD-L2 is thought to control immune T -cell activation in lymphoid 
organs, whereas PD-L1 serves to d ampen unwarranted T-cell funct ion in peripheral tissues (16, 21). 
Binding of either PD-1 ligand to PD-1 inhibits T-cell activatio n triggered through the T-cell receptor 
(18, 22). Although healthy organs  express little (if any) PD-L1 , a variety of cancers were 
demonstrated to express abundant  levels of this T-cell inhibito r including esophageal cancer. PD-1 
has also been suggested to regulate tumor-specific T-cell expan sion in subjects with melanoma (23). 
It has also been shown that blockade of PD-1 pathway leads to T  cell activation and cytokine release 
(24).  
This evidence suggests that the PD-1/PD-L1 pathway plays a crit ical role in evasion of host immune 
system by tumor and should be considered as an attractive targe t for therapeutic intervention. Recent 
data have shown that inhibition of the PD-1 pathway leads to du rable tumor regression (25). Several 
immune checkpoint inhibitors in the form of monoclonal antibodi es to PD-1 and PD-L1 are 
currently being tested in variou s malignancies, both in combina tion with other therapies and as 
single agents. Growing clinical e vidence demonstrates activity of PD-1 pathway inhibitors in 
esophageal cancer including pembro lizumab (PD-1 inhibitor) and durvalumab (MEDI4736). 
Durvalumab is a fully human IgG1 monoclonal antibody against PD -L1 with preliminary data 
demonstrating activity in a vari ety of tumors including esophag eal cancer (26, 27).  
The dynamic PD-1 pathway is impacted by various cancer directed  treatment modalities including 
ionizing radiation. Ionizing radi ation induces a local inflamma tory response that enhances the 
infiltration of tumor-specific T cells and simultaneously upreg ulates PD-1/PD-L1 pathway in the 
tumor microenvironment thereby inhibiting immune activation. Th is upregulation limits some of 
the radiation induced toxicities but at the same time markedly weakens radiation induced antitumor 
immunity facilitating disease relapse. In addition, previous da ta have consistently shown that 
neoadjuvant chemoradiotherapy results in a decrease in the numb er of tumor infiltrating 
lymphocytes (28). It is also know n that higher number of tumor infiltrating lympho cytes have been 
shown to be a prognostic marker a ssociated with decreased dista nt recurrence rate (29). 
Based on these data and the act ivity of durvalumab in esophagea l cancer, we hypothesize that 
adjuvant PD-L1 inhibition followi ng chemoradiotherapy and surge ry in esophageal cancer patients 
who do not achieve a complete pa thological response with trimod ality therapy will decrease the risk 
of cancer recurrence and improve relapse free survival through simulation of the immune system to 
eradicate residual disease. This phase II trial aims to evaluat e the safety and efficacy of durvalumab 
in patients with persistent es ophageal cancer following chemora diotherapy and surgical resection. 
  1.2 Therapeutic Durvalumab (MEDI4736) Background 
MEDI4736 is a human monoclonal antibody (MAb) of the immunoglob ulin G1 kappa (IgG1κ) 
subclass that inhibits binding of  programmed cell death ligand 1 (PD-L1) (B7 homolog 1 [B7-H1], 
cluster of differentiation [CD ]274) to programmed cell death 1 (PD-1; CD279) and CD80 (B7-1). 
MEDI4736 is composed of 2 identical heavy chains and 2 identica l light chains, with an overall 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 11 of 79 molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant 
domain of the immunoglobulin (Ig) G1 heavy chain that reduces b inding to complement protein 
C1q and the fragment crystallizable gamma (Fcγ) receptors invol ved in triggering effector function. 
 1.2.1 Summary of Non-clinical Experience: 
The non-clinical experience is ful ly described in the current v ersion of the durvalumab 
(MEDI4736) Investigato r’s Brochure (IB).    
 MEDI4736 binds with high affinity and specificity to human PD-L 1 and blocks its interaction with 
PD-1 and CD80. In vitro  studies demonstrate that MEDI 4736 antagonizes the inhibitory e ffect of 
PD-L1 on primary human T cells, re sulting in their restored pro liferation and release of interferon 
gamma (IFN-γ). Additionally, ME DI4736 demonstrated a lack of an tibody-dependent cell-mediated 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)  in cell-based functional 
assays. In vivo studies show that MEDI4736 inhibits tumor growt h in a xenograft model via a T 
lymphocyte (T-cell) dependent m echanism. Moreover, an anti-mous e PD-L1 antibody demonstrated 
improved survival in a syngeneic tumor model when given as mono therapy and resulted in complete 
tumor regression in > 50% of treated mice when given in combina tion with chemotherapy. 
Combination therapy (dual targeting of PD-L1 and cytotoxic T-ly mphocyte-associated antigen 4 
[CTLA-4]) resulted in tumor regre ssion in a mouse model of colo rectal cancer.  
Cynomolgus monkeys were selected a s the only relevant species f or evaluation of the 
pharmacokinetics (PK)/pharmacod ynamics and potential toxicity o f MEDI4736. Following 
intravenous (IV) admin istration, the PK of MEDI4736 in cynomolg us monkeys was nonlinear. 
Systemic clearance (CL) decreased and concentration half-life ( t1/2) increased with increasing 
doses, suggesting saturable targ et binding-mediated clearance o f MEDI4736. No apparent gender 
differences in PK profiles were observed for MEDI4736.  
In general, treatment of cynomolgus monkeys with MEDI4736 was n o t  a s s o c i a t e d  w i t h  a n y  
MEDI4736-related adverse effects that were considered to be of relevance to humans. Adverse 
findings in the non-Good Laboratory Practice (GLP) PK/pharmacod ynamics and dose  range-finding 
study, and a GLP 4-week repeat-dose toxicity study were consist ent with antidrug antibody (ADA)-
associated morbidity and mortality in individual animals. The d eath of a single animal in the non-
GLP, PK/pharmacodynamics, and dose range-finding study was cons istent with an ADA-associated 
acute anaphylactic reaction. The spectrum of findings, especial ly the clinical signs and microscopic 
pathology, in a single a nimal in the G LP, 4-week, repeat-dose s tudy was also cons istent with ADA 
immune complex deposition, and ADA:MEDI4736 immune complexes we re identified in a 
subsequent non-GLP, investigative immunohistochemistry study. S imilar observations were 
reported in cynomolgus monkeys administered human mAbs unrelate d to MEDI4736. Given that 
immunogenicity of human mAbs in nonclinical species is generall y not predictive of responses in 
humans, the ADA-associated mor bidity and mortality were not con sidered for the  determination of 
the no-observed-adverse-eff ect level (NOAEL) of MEDI4736.  
Finally, data from the pivotal 3- month GLP toxicity study with MEDI4736 in cynomolgus monkeys 
showed that subchronic dosing of  MEDI4736 was not associated wi
th any adverse effects. 
Therefore, the NOAEL of MEDI4736 in all the general toxicity st udies was considered to be 100 
mg/kg, the highest dose tested in these studies. In addition to  the in vivo  toxicology data, no 
unexpected membrane binding of MEDI4736 to human or cynomolgus monkey tissues was 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 12 of 79 observed in GLP tissue cross-reactivity studies using normal hu man and cynomolgus monkey 
tissues. 
1.2.2 Summary of Clinical Experience: 
Clinical experience with durvalumab (MEDI 4736) is fully describ ed in the current  version of the 
durvalumab (MEDI4736) Inve stigator’s Brochure. 
 As of the data cutoff dates ( 15Apr2015 to 12Jul2015), a total o f 1,883 subjects have been enrolled 
and treated in 30 ongoing MEDI4736 clin ical studies, including 20 sponsored and 10 collaborative 
studies. Of the 1,883 subjects , 1,279 received MEDI4736 monothe rapy, 440 received MEDI4736 
in combination with tremelimumab o r other anticancer agents, 14  received other agents (1 
gefitinib, 13 MEDI6383), and 150 have  been treated with blinded  investigational product. No 
studies have been completed or  terminated prematurely due to to xicity. 
 1.2.3 Pharmacokinetics and Product Metabolism  
MEDI4736 monotherapy exhibited nonlinear (dose-dependent) PK. T he area under the 
concentration-time curve from 0 to 14 days (AUC0-14) increased in a greater than dose-proportional 
manner over the dose range of 0.1 to 15 mg/kg and approached li nearity at ≥ 3 mg/kg, suggesting 
that the nonlinear PK of MEDI4736 is likely due to saturable ta rget-mediated clearance. Exposures 
following multiple doses (currently up to a maximum of 26 doses ) demonstrated accumulation 
consistent with PK parameters estimated from the first dose. Su ppression of free soluble PD-L1 
(sPD-L1) was correlated with M EDI4736 PK concentrations. Follow ing administration of 
MEDI4736 monotherapy, free sPD-L1 l evels were below the lower l imit of quantitation (LLOQ) in 
the majority of subjects with available data (n = 38) at all ti mepoints following IV doses ≥ 1 mg/kg 
every 2 weeks (Q2W).    Overall, a low incidence of ADA was observed. Of the 220 subjec ts who received MEDI4736 
monotherapy and for whom PK/ADA data were available, 5 were det ected ADA positive, with an 
impact on PK/pharmacodynamic s reported in 1 subject.  
 1.2.4 Safety:   
The safety profile of MEDI4736 a s monotherapy and combined with  other anticancer agents was 
consistent with the pharmacology o f the target and other agents  in the immune checkpoint 
inhibitor class. No tumor types appeared to be associated with unique AEs. Immune-mediated AEs 
(imAEs), which are important ris ks of immune checkpoint inhibit ors, have been observed with 
MEDI4736 and include colitis, pneum onitis, hepatitis/hepatotoxi city, neuropathy/neuromuscular 
toxicity, endocrinopathy, derm atitis, and nephritis. In additio n, pancreatitis is an important 
potential risk particularly wit h MEDI4736 and tremelimumab comb ination therapy. These events 
are manageable by available/esta blished treatment guidelines as  described in the study protocols. 
 AEs reported with MEDI4736 monoth erapy and MEDI4736 and tremeli mumab combination 
therapy in key clinical st udies are described below. 
 
1.2.4.1  
Adverse Event Profile of Dur valumab (MEDI4736) Monotherapy 
Study CD-ON-MEDI4736-1108: The safety profile of MEDI4736 monotherapy in the 694 subjects 
with advanced solid tumors treated at 10 mg/kg Q2W in Study CD- ON-MEDI4736-1108 has been 
broadly consistent w ith that of the overall 1,279 subjects who have received MEDI4736 
monotherapy (not including subjects treated with blinded invest igational product) acr oss the clinical 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 13 of 79 development program. The major ity of treatment-related AEs were  manageable with dose delays, 
symptomatic treatment, and in the case of events suspected to h ave an immune basis, the use of 
established treatment guidelines for immune-mediated toxicity. As of 07May2015, among the 694 
subjects treated with MEDI4736 10 mg/kg Q2W in Study CD-ON-MEDI 4736-1108, a total of 378 
subjects (54.5%) experienced a t reatment-related AE, with the m ost frequent (occurring in ≥ 5% of 
subjects) being fatigue (17.7%),  nausea (8.6%), diarrhea (7.3%) , decreased appetite (6.8%), pruritus 
(6.3%), rash (6.1%), and vomiting (5.0%). A majority of the tre atment-related AEs were Grade 1 or 
Grade 2 in severity with ≥ Grade 3 events occurring in 65 subje cts (9.4%). Treatment-related ≥ 
Grade 3 events reported in 3 or  more subjects (≥ 0.4%) were fat igue (12 subjects, 1.7%); increased 
aspartate aminotransferase (AS T; 7 subjects, 1.0%); increased g amma-glutamyltransferase (GGT; 
6 subjects, 0.9%); increased ala nine aminotransferase (ALT; 5 s ubjects, 0.7%) ; and colitis, 
vomiting, decreased appetite, a nd hyponatremia (3 subjects, 0.4 % each). Six subjects had treatment-
related Grade 4 AEs (upper gastro intestinal hemorrhage, increas ed AST, dyspnea, neutropenia, 
colitis, diarrhea, and pneumoniti s) and 1 subject had a treatme nt-related Grade 5 event (pneumonia). 
Treatment-related serious adverse events (SAEs) that occurred i n ≥ 2 subjects were colitis and 
pneumonitis (3 subjects each). A  majority of the treatment-rela ted SAEs were ≥ Grade 3 in severity 
and resolved with or without sequelae. AEs that resulted in per manent discontinuation of MEDI4736 
were considered as treatment related in 18 subjects (2.6%), wit h colitis being the most frequent 
treatment-related AE resulting in discontinuation (3 subjects).  A majority of the treatment-related 
AEs resulting in discontinuation of MEDI4736 were ≥ Grade 3 in severity and resolved with or 
without sequelae.  Study D4191C00003/ATLANTIC: The safety profile of MEDI4736 monotherapy in Study CD-
ON-MEDI4736-1108 is generally consistent with that of Study D41 91C00003/ATLANTIC in 
subjects with locally advanced or metastatic non-small cell lun g cancer (NSCLC) treated with 
MEDI4736 10 mg/kg Q2W. As of 05May2015, 264 of 303 subjects (87 .1%) reported any AE in 
Study D4191C00003/ATLANTIC. Overall,  events reported in ≥ 10% o f subjects were dyspnea 
(18.8%), fatigue (17.8%), decreased appetite (17.5%), cough (14 .2%), pyrexia (12.2%), asthenia 
(11.9%), and nausea (11.2%). Nearly two-thirds of the subjects experienced AEs that were Grade 1 
or 2 in severity and manageable  by general treatment guidelines  as described in the current 
MEDI4736 study protocols. Grade 3 o r higher AEs were reported i n 107 of 303 subjects (35.3%). 
A total of 128 subjects (42.2%) reported AEs that were consider ed by the investigator as related to 
investigational product. Treatment-related AEs (all grades) rep o r t e d  i n  ≥  2 %  o f  s u b j e c t s  w e r e  
decreased appetite (6.6%); fati gue (5.9%); asthenia (5.0%); nau sea (4.6%); pruritus (4.3%); 
diarrhea, hyperthyroidism, hypothyr oidism, and pyrexia (3.3% ea ch); rash (2.6%); weight decreased 
(2.3%); and vomiting (2.0%). Trea tment-related Grade 3 AEs repo rted in ≥ 2 subjects were 
pneumonitis (3 subjects) and incr eased GGT (2 subjects). There was no treatment-related Grade 4 
or 5 AEs. Ninety-four of 303 s ubjects (31.0%) reported any SAE.  SAEs that occurred in ≥ 1.0% of 
subjects were dyspnea (6.6%); ple ural effusion, general physica l health deterioration (2.3% each); 
pneumonia (2.0%); hemoptysis, pulm onary embolism (1.3% each); a nd pneumonitis, respiratory 
failure, disease progression (1.0% each). Nine subjects had an SAE considered by the investigator 
as related to MEDI4736. Each tr eatment-related SAE occurred in 1 subject each with the exception 
of pneumonitis, which occurred in 3 subjects. Fifteen of 303 su bjects (5.0%) have died due to an 
AE (pneumonia [3 subjects]; gene ral physical health deteriorati on, disease progression, hemoptysis, 
dyspnea [2 subjects each ]; pulmonary sepsis, respiratory distre ss, cardiopulmonary arrest [verbatim 
term (VT)], hepatic failure, a nd sepsis [1 subject each]). None  of these events was considered related 
to MEDI4736. Twenty-three of 303 subjects (7.6%) permanently di scontinued MEDI4736 treatment 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 14 of 79 due to AEs. Events that led to discontinuation of MEDI4736 in ≥  2 subjects were dyspnea, general 
physical health deterioration, and pneumonia. Treatment-related  AEs that led to discontinuation 
were increased ALT and increase d hepatic enzyme, which occurred  in 1 subject each. 
 1.2.5 Efficacy:   
Partial efficacy data are ava ilable for 2 monotherapy studies ( CD-ON-MEDI4736-1108 and 
D4190C00007) and 2 combination the rapy studies (CD-ON-MEDI4736- 1161 and D4190C00006). 
Clinical activity has been obs erved across the 4 studies. 
 Study CD-ON-MEDI4736-1108: Overall, 456 of 694 subjects trea ted with MEDI4736 10 mg/kg 
Q2W were evaluable for response (defined as having ≥ 24 weeks f ollow-up, measurable disease at 
baseline, and ≥ 1 follow-up sca n, or discontinued due to diseas e progression or death without any 
follow-up scan). In PD-L1 unselec ted patients, the objective re sponse rate (ORR), based on 
investigator assessment per Res ponse Evaluation Criteria in Sol id Tumors (RECIST) v1.1, ranged 
from 0% in uveal melanoma (n =  23) to 20.0% in bladder cancer ( n = 15), and disease control rate 
at 24 weeks (DCR-24w) ranged from  4.2% in triple-negative breas t cancer (TNBC; n = 24) to 
39.1% in advanced cutaneous melanom a (n = 23). PD-L1 status was  known for 383 of the 456 
response evaluable subjects. Across the PD-L1-positive tumors, ORR was highest for bladder 
cancer, advanced cutan eous melanoma, hepato cellular carcinoma ( HCC; n = 3 each, 33.3% each), 
NSCLC (n = 86, 26.7%), and squamous c ell carcinoma of the head and neck (SCCHN; n = 22, 
18.2%). In the PD-L1-positive subset, DCR-24w was highest in ad vanced cutaneous melanoma (n 
= 3, 66.7%), NSCLC (n = 86, 36.0%), HCC and bladder cancer (n =  3 each, 33.3% each), and 
SCCHN (n = 22, 18.2%).  Study D4190C00007: Of the 32 subjects with myelodys plastic syndrome (MDS) treated in Study 
D4190C00007, 21 subjects had at leas t 1 post-baseline disease a ssessment. Among these subjects, 
the best overall responses were ma rrow complete remission (mCR)  in 4 subjects (19.0%); stable 
disease (SD) in 4 subjects (19.0% ); and progressive disease (PD ) in 5 subjects (23.8%). The 
remaining 8 subjects (38.1%) did no t meet the criteria for comp lete remission (CR), mCR, partial 
remission (PR), SD, or PD at  the date of assessment. 
 Study CD-ON-MEDI4736-1161: Of the 65 subjects with metasta tic or unresectable melanoma 
treated with the combination of M EDI4736 and BRAF inhibitor (BR AFi; dabrafenib)/MEK 
inhibitor (MEKi; trametinib), 63 s ubjects were evaluable for re sponse. A total of 35 subjects 
(55.6%) had a best overall respons e of confirmed or unconfirmed  PR. The disease control rate 
(DCR; CR + PR [regardless of con firmation] + SD ≥ 12 weeks) was  79.4%. 
 Study D4190C00006: Of the 102 subjects with advanced NSCLC treated with MEDI4736 i n 
combination with tremelimuma b in Study D4190C00006, 63 subjects  with at least 16 weeks of 
follow-up were evaluable for response (defined as measurable di sease at baseline and at least 1 
follow-up scan; this included discontinuations due to disease p rogression or death without follow-
up scan). Of the 63 evaluable subjects, 17 (27%) had a best ove rall response of PR, 14 (22%) had 
SD, 22 (35%) had PD, and 10 (16%) were not evaluable. The ORR ( confirmed and unconfirmed 
CR or PR) was 27% and the DCR ( CR, PR, or SD) was 49% as assess ed by RECIST v1.1. 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 15 of 79 1.3 Durvalumab (MEDI4736) Fixed Dosing 
A population PK model was develo ped for MEDI4736 using monother apy data from a Phase 1 
study ( study 1108; N=292; doses= 0.1 to 10 mg/kg Q2W or 15 mg/kg Q3W; solid tumors ). 
Population PK analysis indica ted only minor impact of body weig ht (WT) on PK of MEDI4736 
(coefficient of ≤ 0.5). The impact of body WT-based (10 mg/kg Q 2W) and fixed dosing (750 mg 
Q2W) of MEDI4736 was evaluated by comparing predicted steady st ate PK concentrations (5th, 
median and 95th percentiles) using the populatio n PK model. A fixed dose of 75 0 mg was selected 
to approximate 10 mg/kg (base d on median body WT of ~75 kg). A total of 1000 patients were 
simulated using body WT dist ribution of 40–120 kg. Simulation r esults demonstrate that body 
WT-based and fixed dosing regimens  yield similar m edian steady state PK concentrations with 
slightly less overall between-s ubject variability with fixed do sing regimen.   
 Similar findings have been re ported by others. Wang and colleag ues investigated 12 monoclonal 
antibodies and found that fixe d and body size-based dosing perf orm similarly, with fixed dosing 
being better for 7 of 12 antibodi es. In addition, they investig ated 18 therapeutic proteins and 
peptides and showed that fixe d dosing performed be tter for 12 o f 18 in terms of reducing the 
between-subject variability i n pharmacokinetic/pharmacodynamics  parameters. (30) 
 A fixed dosing approach is prefer red by the prescribing communi ty due to ease of use and reduced 
dosing errors. Given expectation of  similar pharmacokinetic exp osure and variability, AstraZeneca 
considered it feasible to sw itch to fixed dosing regimens. Base d on average body WT of 75 kg, a 
fixed dose of 1500 mg Q4W MEDI4736 ( equivalent to 20 mg/kg Q4W)  is included in the current 
study. Fixed dosing of durvalumab i s recommend only for subject s with > 30kg body weight due 
to endotoxin exposure.  Patient s with a body weight less than o r equal to 30 kg should be dosed 
using a weight-based dosing schedule.   2. OBJECTIVES, ENDPOINTS A ND OUTCOME MEASURES 
 2.1.Objectives  
2.1.1.  Primary Objective:  
 To determine if postoperative ad juvant therapy with durvalumab improves 1 year 
relapse free survival (RFS) com pared to historical rates in pat ients with persistent 
esophageal cancer following neoadj uvant chemoradiotherapy and e sophagectomy. 
 
2.1.2.  Secondary Objectives 
 To assess the toxicity and tol erability of durvalumab following  trimodality therapy 
in patients with esophageal cancer.  
 
2.1.3.  Correlative/ Exploratory Objectives 
 To assess changes in PD-L1 expr ession with chemoradiotherapy in  esophageal 
cancer.  
 To analyze possible predictive bi omarkers of 1 year RFS includi ng PD-L1 
expression (at diagnosis and in res idual disease)  in tumor cell s and tumor 
infiltrating lymphocytes (by hist ology and gene expression anal ysis – by pathway 
analysis and CIBERSORT), both w ithin the tumor and in surroundi ng connective 
tissue. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 16 of 79  To assess the Immunoscore (ba sed on numeration of lymphocyte po pulations - 
CD3/CD45RO, CD3/CD8, CD8/CD45RO)  – within the center and invasi ve 
margins of the tumor – and co rrelate it wit h 1 year RFS. 
 To analyze the correlation betw een changes in circulating tumor  cell numbers in 
response to PD-L1 inhibition and 1 year RFS in patients with re sidual esophageal 
cancer. 
 2.2.Endpoints 
2.2.1.  Primary Endpoint  
1 year relapse free survival 
 
2.2.2.  Secondary Endpoints  
Toxicity and tolerability of PD -L1 inhibition after trimodality  therapy in patients 
with esophageal cancer. 
 
2.3.Outcome Measures 
2.3.1.  Primary Outcome Measure 
Relapse free survival at 1 year . History and physical examinati on to be performed 
every 4 weeks while the patient i s receiving durvalumab. CT sca n of the chest and 
abdomen will be performed ever y 3 months to asse ss for disease recurrence.  
 
2.3.2.  Secondary Outcome Measures  
Incidence and severity of adverse events related to the study d rug – to be assessed 
at every visit, which will be e very 4 weeks prior to the next d ose of durvalumab. 
 We will also collect data on re gimen received (carboplatin/pacl itaxel or cisplatin/5-FU), histology 
(adenocarcinoma), and amount and s ite of residual disease (prim ary tumor only or with lymph node 
involvement) for desc riptive purposes. 
 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 17 of 79 3. ELIGIBILITY CRITERIA 
 3.1.Inclusion Criteria  
 
Subject must meet all  of the following app licable inclusion cri teria to participate in this study: 
 3.1.1 Written informed cons ent and HIPAA authoriz ation for release of  protected health 
information obtained from the su bject prior to performing any p rotocol-related procedures, 
including screening evaluations. 
NOTE:   HIPAA authorization may be inc luded in the informed consent o r obtained 
separately. 
 
3.1.2 Age ≥ 18 years at the time of consent. 
 
3.1.3 ECOG Performance Status of 0-1 w ithin 28 days prior to registra tion for protocol therapy. 
 
3.1.4 Females of childbearing potenti al and males must be willing to use two effective methods 
of contraception (See section 5.5.1) from the time consent is s igned until 3 months after 
treatment discontinuation. 
 
3.1.5 Females of childbearing potential  must have a negative serum pr egnancy test within 14 days 
prior to registration for protocol therapy. 
NOTE:   Female subjects are considere d of childbearing potential unle ss they are surgically 
sterile (they have undergone a hys terectomy, bilate ral tubal li gation, or bilateral 
oophorectomy) or they are ≥60 ye ars old and naturally postmenop ausal for at least 12 
consecutive months. See section 5.5.1. 
 
3.1.6 Histological evidence of persiste nt residual esophageal adenoca rcinoma including 
gastroesophageal junction adenocar cinoma following definitive c oncurrent 
chemoradiotherapy (carboplatin a nd paclitaxel or cisplatin and 5-FU) in the surgical sample 
(esophagus or lymph node or both) obtained at the time of esoph agectomy.  
NOTE : Persistent residual disease is defined as follows (modified f rom College of 
American Pathologists Guidelines): 
- No residual tumor (Grade 0, compl ete response, 0% tumor). This group will not be 
included in this study. 
- Marked response (Grade 1, 0-<10% residual tumor) 
- Moderate response (Grade 2, 10-50% residual tumor) 
- No definite response (Grade  3, >50% residual tumor) 
 3.1.7 Minimum of 1 month and maximum of  3 months from surgical resect ion with no evidence 
of disease progression at t he time of enrollment. 
 
3.1.8 Must have adequately recovered from surgery as judged by the tr eating investigator. 
 3.1.9 Laboratory values must be obtai ned within 28 days prior to regi stration for protocol 
therapy.   
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 18 of 79  White blood cell count (WBC) > 3 K/mm3 
 Hemoglobin (Hgb) > 9 g/dL. Trans fusion is allowed, if needed, s ince patients are post 
esophagectomy.  
 Platelets >  100 K/mm3 
 Absolute neutrophil count (ANC) ≥ 1.5 K/mm3 
 Calculated creatinine clearan ce of > 40 cc/min using the Cockcr oft-Gault formula or by 
24-hour urine collection for dete rmination of cr eatinine cleara nce: 
  
Males:  (140 – Age in years) ×  Actual Body Weight in kg 
 72 × Serum Creatinine (mg/dL) 
 
Females:  Estimate d creatinine cleara nce for males × 0.85 
 Bilirubin ≤ 1.5  ULN 
 Aspartate aminotransferase (AST, SGOT) < 2.5  ULN 
 Alanine aminotransferase (ALT, SGPT) < 2.5  ULN 
 
3.1.10  Subject is willing and able to com ply with the pro tocol for the  duration of the study 
including undergoing treatment a nd scheduled vis its and examina tions including follow up. 
 3.2. Exclusion Criteria 
 
Subjects meeting any of the criteria below may not participate in the study: 
 3.2.1 Prior therapy with a PD-1, PD-L 1, or CTLA-4 inhibitor or cancer -specific vaccine therapy. 
 
3.2.2 Evidence of active autoimmune disease requiring systemic treatm ent within preceding 3 
months or a documented history of clinically severe autoimmune disease, or a syndrome 
that requires systemic steroid s or immunosuppressive agents. Ex ceptions to this rule 
include vitiligo, resolved chil dhood asthma/atopy, requirement of intermittent 
bronchodilators or local steroi d injections, hypothyroidism sta ble on hormone replacement, 
psoriasis not requiring systemic treatment (within the past 2 y ears), Graves’s disease and 
Sjogren’s syndrome.  
3.2.3 Prior malignancy is not allowed e xcept for adequately treated b asal cell or squamous cell 
skin cancer, in situ cervical cancer, Gleason sco re ≤ 7 prostat e cancers, or other cancer for 
which the subject has been dis ease-free for at  least 3 years. 
 3.2.4 Active or prior documented infla mmatory bowel disease (e.g. Cro hn’s disease, ulcerative 
colitis).  
3.2.5 Presence of interstitial lung di sease or history of pneumonitis  requiring treatment with 
corticosteroids.  
3.2.6 Patients with diagnosis of  primary immunodeficiency. 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 19 of 79 3.2.7 Patients receiving chronic syste mic corticosteroid therapy or o ther immunosuppressive 
therapy within 28 days prior to reg istration for protocol thera py. Exceptions include 
intranasal and inhaled corticoste roids or systemi c corticostero ids at physiological doses, 
which are not to exceed 10 mg/da y of prednisone, or an equivale nt corticosteroid. 
 
3.2.8 History of allogeneic organ or  stem cell transplant. 
 
3.2.9 Receipt of live attenuated vacci ne within 30 days prior to regi stration for prot ocol therapy. 
 
3.2.10  Mean QT interval corrected for  heart rate (QTc) > 470 msec calc ulated from 3 ECGs by 
Bazett’s Correction.  
3.2.11  Ventricular arrhythmias requiring medication(s). 
 
3.2.12  Uncontrolled intercurrent illn ess including, but not limited to , symptomatic congestive 
heart failure, uncont rolled hypertension, unstable angina pecto ris, cardiac arrhythmia, 
active peptic ulcer d isease or gastritis, or  active bleeding di atheses.  
 
3.2.13  History of psychiatric illness/so cial situations that would lim it compliance with study 
requirements or compromise the ability of the subject to give w ritten informed consent. 
 
3.2.14  Known HIV infection or ch ronic hepatitis B or C. 
 
3.2.15  Known history of previous clinical  diagnosis of tuberculosis. 
 
3.2.16  Clinically significan t infections as judge d by the treating inv estigator. Clinically significant 
is defined as an active infect ion requiring IV antibiotics. 
 
3.2.17  Because there is an unknown but potential risk for adverse even ts in nursing infants 
secondary to treatment of the m other, breastfeeding should be d iscontinued.  In addition, 
breast milk cannot be stored for f uture use while the mother is  being treated on study. 
 
3.2.18  Treatment with any investigationa l agent withi n 28 days prior t o registration for protocol 
therapy.   
3.2.19  History of hypersensitivity t o durvalumab or any excipient. 
 
3.2.20  Any condition that, in the opinion o f the investigator, would i nterfere with evaluation of 
study treatment or inter pretation of patient  safety or study re sults. 
 
3.2.21  Previous enrollment in the present study. 
 
 4. SUBJECT REGISTRATION   
All subjects must be registered and randomized through Big Ten CRC Administrative Headquarters’ 
electronic data capture (EDC) system. A subject is considered r egistered when an ‘On Study’ date 
is entered into the EDC system. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 20 of 79  
Subjects must be registered prior  to starting protocol therapy.  Subjects must begin therapy within 
five business days of  registration.  
 Blinding This study treatment is not blin ded to the subject or the inves tigator. 
 5. TREATMENT PLAN 
 5.1.Pre-medication  
None 
 5.2.Drug Administration 
 
Drug Dose Frequency of 
administrationRoute of 
administrationNumber of cycles 
Durvalumab 1500 mg1 Every 4 weeks 
(1 cycle) Intravenous Maximum 13 doses (12 
months), or until 
unacceptable toxicities or 
disease recurrence
1: Based on average body weight of 75 kg, a fixed dose of 1500 m g Q4W durvalumab (equivalent 
to 20 mg/kg Q4W) is included in the current study. Fixed dosing  of durvalumab is recommended 
only for subjects w ith > 30kg body weight due to endotoxin expo sure.  Patients w ith a body weight 
less than or equal to 30 kg should be  dosed using a weight-base d dosing schedule. 
 NOTE:  Infusions may be given ±3 days for reasons such as observed ho lidays, inclement weather, 
scheduling conflicts, etc. It s hould be clearly documented in s ubject’s chart and cas e report forms. 
 The body surface area and drug dose should be recalculated only  if subject’s weight changes by       
≥ 10% during the course of the study.  
5.2.1.  Missed doses:  
Missed doses can be made up within 8 days of the missed dose. 
 
5.3. Supportive Care:  
Institutional standards shoul d be followed for hydration and tr ansfusions. 
 
5.4. Concurrent Therapy 
None 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 21 of 79 5.5. Restrictions during the study 
The following medications are considered exclusionary  during the study.  
1. Any investigational anticancer t herapy other than the protocol specified therapy 
2. Any concurrent chemotherapy, rad iotherapy, immunotherapy, biolo gic or hormonal therapy 
for cancer treatment, other than a ny stated comparator or combi nation regimens. Concurrent 
use of hormones for noncancer-re lated conditions (e.g., insulin  for diabetes and hormone 
replacement therapy) is acceptable.   
3. Immunosuppressive medications i ncluding, but not l imited to, sy stemic corticosteroids at 
doses exceeding 10 mg/day of predni sone or equivalent, methotre xate, azathioprine, and TNF-
α blockers. Use of immunosuppressi ve medications for the manage ment of investigational 
product-related AEs or in subjects  with contrast allergies is a cceptable. In addition, use of 
inhaled and intranasal corticost eroids is permi tted. A temporar y period of steroids will be 
allowed for different indicati ons, at the discretion of the pri ncipal investigator (e.g., chronic 
obstructive pulmonary diseas e, radiation, na usea, etc). 
4. Live attenuated vaccines with in 30 days of durvalumab dosing (i e, 30 days prior to the first 
dose, during treatment with durva lumab and for 30 days post dis continuation of durvalumab.)  
Inactivated viruses, such as those in the influenza vaccine, ar e permitted. 
 5.5.1.Contraception  
Females of childbearing potential  who are sexually active with a nonsterilized male partner must 
use 2 methods of effective contraception from screening, and mu st agree to continue using such 
precautions for 3 months (90 days) after the final dose of inve stigational product, or for at least 90 
days following the last infusi on of durvalumab; cessation of bi rth control after th is point should be 
discussed with a responsible phys ician.  Periodic abstinence, t he rhythm method, and the 
withdrawal method are not acceptable methods of birth control.  
 Female subjects are considered o f childbearing potential unless  they are surgically sterile (they 
have undergone a hysterectomy, bila teral tubal ligation, or bil ateral oophorectomy) or they are 
≥60 years old and naturally postmen opausal for at least 12 cons ecutive months. 
 Subjects must use 2 acceptable me thods of effective contracepti on as described in the table 
below. 
 Nonsterilized males who are sexua lly active with a female partn er of childbear ing potential 
must use 2 acceptable methods of  effective contraception (see T able 1 below) from Day 1 and 
for 90 days after receipt of the final dose of i nvestigational product. 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 22 of 79 Table 1 Effective methods of contraception (two methods must be  used) 
Barrier Methods Intrauterine Device Methods Hormonal 
Methods 
Male condom plus spermic ide Copper T Implants 
Cap plus spermicide Progesterone Ta Hormone injection 
Diaphragm plus spermicide Levonorgestrel-releasing 
intrauterine system (e.g., Mirena®)a Combined pill
Minipill 
Patch 
a This is also consider ed a hormonal method. 
 
5.5.2.Blood donation 
Subjects should not donate blood whi le participating in this st udy and for at least 90 days 
following the last inf usion of durvalumab. 
 
 6. DOSE MODIFICATIONS  
The NCI Common Terminology Criter ia for Adverse Events (CTCAE) Version 4 will be used to 
grade adverse events.  Subjects enrolled in this study will be evaluated clinically an d with standard laboratory tests before 
and at regular intervals during their participation in this stu dy as specified in the Study Calendar and 
Evaluations section.  Subjects will be evaluated for adverse events (all grades), ser ious adverse events, and adverse events 
requiring protocol therapy interru ption or discontinuation at e ach study visit for the duration of their 
participation in the study.    Subjects discontinued from the treatment phase of the study for  any reason will be evaluated at least 
30 days (+ 7) after the last  dose of protocol therapy. 
  
6.1. Dose Modifications 
 
6.1.1.  Dose Modifications and Toxici ty Management for Durvalumab: 
 For adverse events (AEs) that are considered at least partly du e to administration of durvalumab the 
following dose adjustment guidance may be applied: 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 23 of 79  Treat each of the toxicities with maximum supportive care (incl uding holding the agent 
suspected of causing the t oxicity where required). 
 If the symptoms promptly resol ve with supportive care, consider ation should be given to 
continuing the same dose of durvalumab along with appropriate c ontinuing supportive care.  If 
medically appropriate, dose modifi cations are permitted for dur valumab (see below). 
 All dose modifications should be d ocumented with clear reasonin g and documentation of the 
approach taken. 
 
In addition, there are certain c ircumstances in which durvaluma b should be permanently 
discontinued.  Following the first dose of durvalumab, subsequent administrati on of durvalumab can be modified 
based on toxicities observed ( see Tables 2, 3 and 4 below). Dos e reductions are not permitted .  
 Based on the mechanism of action of durvalumab leading to T-cel l activation and pr oliferation, there 
is the possibility of observing i mmune-mediated Adverse Events (imAEs) during the conduct of this 
study.  Potential imAEs include immune-mediated enterocolitis, dermatitis, hepatitis, and 
endocrinopathies. Subjects shoul d be monitored for signs and sy mptoms of imAEs.  In the absence 
of an alternate etiology (e.g., in fection or PD) signs or sympt oms of enterocolitis, dermatitis, 
hepatitis, and endocrinopathy s hould be considered to be immune -related.   
 Dose modification recommendations and toxicity management guide lines for immune-mediated 
adverse events, for infusion-re lated reactions, and for non-imm une-mediated adverse events are 
detailed in Tables 2, 3, and 4, respectively.    In addition, management guidelines for adverse events of specia l interest (AESIs) are detailed in 
Section 10.1.3. All toxicities will  be graded according to NCI CTCAE v4. 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 24 of 79 Table 2  Dosing Modifications and Toxicity Management Guideline s for Immune-Mediated, Infusion Related,  
and Non Immune-mediated Reactions  for Durvalumab Monotherapy (1  November 2017 Version) 
General Considerations 
Dose Modifications Toxicity Management 
Drug administration modifications of study drug/study regimen w ill be made to 
manage potential immune-related  AEs based on severity of treatm ent-emergent 
toxicities graded per NCI CTCAE v4. 
In addition to the criteria for permanent discontinuation of st udy drug/regimen based 
on CTC grade/severity (table below), permanently discontinue st udy drug/study 
regimen for the following conditions:  
 Inability to reduce corticosteroid  to a dose of ≤10 mg of predn isone per day (or 
equivalent) within 12 weeks  after last dose of study drug/regimen 
 Recurrence of a previously experi enced Grade 3 treatment-relate d AE following 
resumption of dosing. It is recommended that management of immune-mediated 
adverse events (imAEs) follow the guidelines presented in this table 
- It is possible that events with an inflammatory or immune 
mediated mechanism could occu r in nearly all organs, some 
of them not noted specifically in these guidelines. 
- Whether specific immune-m ediated events (and/or 
laboratory indicators of such events) are noted in these guidelines or not, patients should be thoroughly evaluated to rule out any alternative etio logy (e.g., disease progression, 
concomitant medications, and infections) to a possible 
immune-mediated event. In the absence of a clear alternative 
etiology, all such events should be managed as if they were 
immune related. General recommendations follow. 
- Symptomatic and topical thera py should be considered for 
low-grade (Grade 1 or 2, unless otherwise specified) events  
- For persistent (greater than 3 to  5 days) low-grade (Grade 2)  
or severe (Grade ≥3) events, p romptly start prednisone 1 to 2 
mg/kg/day PO or IV equivalent.  
- Some events with high like lihood for morbidity and/or 
mortality – e.g., myocarditis, or other similar events even if 
they are not currently noted in the guidelines – should progress rapidly to high dose IV corticosteroids 
(methylprednisolone at 2 to 4 mg/kg/day) even if the event 
is Grade 2, and if clinical suspi cion is high and/or there has 
been clinical confirmation. Consider, as necessary, discussing with the study physician, and promptly pursue specialist consultation. 
- If symptoms recur or worsen dur ing corticosteroid tapering 
(28 days of taper), increase the corticosteroid dose 
(prednisone dose [e.g. up to 2-4 mg/kg/day PO or IV 
equivalent]) until stabilization or improvement of symptoms, Grade 1 No dose modification 
Grade 2 Hold study drug/study regimen dose until grade 2 resolu tion to ≤ Grade 1 
• If toxicity worsens then treat as Grade 3 or Grade 4 
• Study drug/study regimen can be resumed once event stabilizes t o Grade 
≤1 after completion of steroid taper. 
• Patients with endocrinopathies w ho may require prolonged or con tinued 
steroid replacement can be retreated with study drug/study regi men on 
the following conditions: 
1. The event stabilizes and is controlled. 
2. The patient is clinically stable as per Investigator or treatin g 
physician’s clinical judgement. 
3. Doses of prednisone are at ≤10 mg/day or equivalent.
Grade 3 •  Depending on the individual toxicity, may permanently discontin ue 
study drug/study regimen. Please refer to guidelines below 
Grade 4 Permanently discontinue study drug/study regimen  
Note :  For Grade 3 and above asympto matic amylase or lipase levels hold study 
drug/regimen and if complete work up shows no evidence of pancr eatitis, may 
continue or resume study drug/regimen.  
Note : Study drug/study regimen should be permanently discontinued i n Grade 3 
events with high likelihood for morbidity and/or mortality – e. g., myocarditis, or other 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 25 of 79 Table 2  Dosing Modifications and Toxicity Management Guideline s for Immune-Mediated, Infusion Related,  
and Non Immune-mediated Reactions  for Durvalumab Monotherapy (1  November 2017 Version) 
General Considerations 
Dose Modifications Toxicity Management 
similar events even if they are not currently noted in the guid elines. Similarly, 
consider whether study drug/st udy regimen should be permanently  discontinued in 
Grade 2 events with high likelihood for morbidity and/or mortal ity – e.g., myocarditis, 
or other similar events even if t hey are not currently noted in  the guidelines – when 
they do not rapidly improve to Grade <1 upon treatment with sys temic steroids and 
following full taper. 
 Note : There are some exceptions to permanent discontinuation of stu dy drug for 
Grade 4 events (i.e., hyperthyroidism, hypothyroidism, Type 1 d iabetes mellitus). then resume corticosteroid tapering at a slower rate 
(>28 days of taper). 
- More potent immunosuppressives such as TNF inhibitors 
(eg, infliximab) (also refer to individual sections of the 
immune-related adverse event for specific type of 
immunosuppressive) should be c onsidered for events not 
responding to systemic steroids. Progression to use of more potent immunosuppressives should proceed more rapidly in events with high likelihood for morbidity and/or mortality – 
e.g., myocarditis, or other similar events even if they are not  
currently noted in the guidelines – when these events are not 
responding to systemic steroids. 
- With long-term steroid and other immunosuppressive use, 
consider need for Pneumocys tis jirovecii pneumonia (PJP, 
formerly known as Pneumocystis carinii pneumonia) prophylaxis, gastrointestinal protection, and glucose monitoring. 
- Discontinuation of study drug is  not mandated for Grade 3 / 
Grade 4 inflammatory reactions attributed to local tumour 
response (e.g. inflammatory reaction at sites of metastatic 
disease and lymph nodes). Continuation of study drug in this situation should be based upon  a benefit/risk analysis for 
that patient.  
AE  Adverse event; CTC  Common Toxicity Criteria; CTCAE  Common  Terminology Criteria for Advers e Events; imAE  Immune-mediated  adverse event; IV  intravenous; 
NCI  National Cancer Institute; PO  By mouth.  
 
  
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 26 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
 
Pneumonitis/ 
Interstitial Lung 
Disease (ILD) Any Grade General Guidance For Any Grade: 
- Monitor patients for signs a nd symptoms of pneumonitis 
or ILD (new onset or worsening shortness of breath or 
cough).  Patients should be e valuated with imaging and 
pulmonary function tests including other diagnostic procedures as described below. 
- Initial work-up may include clinical evaluation, 
monitoring of oxygenation via pulse oximetry (resting and 
exertion), laboratory work-up and high-resolution CT 
scan. 
Grade 1  (Asymptomatic, clinical or diagnostic observations only, intervention not 
indicated) No dose modification required. 
However, consider holding study drug/study regimen dosing as clinically appropriate and duri ng diagnostic work-
up for other etiologies. For Grade 1  (Radiographic Changes Only) 
- Monitor and closely follow up in 2-4 days for clinical 
symptoms, pulse oximetry (resting and exertion) and laboratory work-up and then as clinically indicated. 
- Consider pulmonary and in fectious disease consult. 
Grade 2  
(Symptomatic, 
medical intervention indicated, limiting instrumental ADL)  Hold study drug/study regimen dose 
until grade 2 resolution to ≤ Grade 1. 
• If toxicity worsens then treat as 
Grade 3 or Grade 4.  
• If toxicity improves to ≤ Grade 1 
then the decision to reinitiate study 
drug/regimen will be based upon 
treating physician’s clinical judgment and after completion of steroid taper.  
  For Grade 2  (Mild to Moderate New Symptoms) 
- Monitor symptoms daily and consider hospitalization 
- Promptly start systemic ster oids (e.g., prednisone 1 to 2 
mg/kg/day PO or IV equivalent). 
- Reimaging as clinically indicated. 
- If no improvement within 3-5 days, additional workup 
should be considered and prompt treatment with IV 
methylprednisolone 2 to 4 mg/kg/day started. 
- If still no improvement within 3-5 days despite IV 
methylprednisolone at 2-4/g/kg/day, promptly start immunosuppressive therapy such as TNF inhibitors 
(infliximab at 5 mg/kg every 2 weeks). Caution : 
Important to rule out sepsis and refer to infliximab label for general guidance before using infliximab.  
- Once improving, gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungal or anti 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 27 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
PJP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections (Category 2B 
recommendation)i 
- Consider pulmonary and in fectious disease consult. 
- Consider, as necessary, di scussing with study sponsor-
investigator via the Big Ten CRC project manager.
Grade 3 or 4  (Grade 3: Severe symptoms; limiting 
self-care ADL; 
oxygen indicated)  (Grade 4: life threatening respiratory 
compromise, urgent 
intervention indicated [e.g. tracheostomy or intubation])  Permanently discontinue study 
drug/study regimen  For Grade 3 or 4  (severe or new symptoms, new/worsening 
hypoxia, life threatening):  
- Promptly initiate empiric IV methylprednisolone 1 to 4 
mg/kg/day or equivalent  
- Obtain pulmonary and infecti ous disease consult; consider, 
as necessary, discussing with sponsor investigator. 
- Hospitalize the patient 
- Supportive Care (eg, oxygen) 
- If no improvement within 3-5 days, additional workup 
should be considered and prom pt treatment with additional 
immunosuppressive therapy such as TNF inhibitors (eg, infliximab at 5mg/kg every 2 weeks dose) started. Caution : rule out sepsis and refer to infliximab label for 
general guidance before using infliximab  
- Once improving, gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungals and in 
particular, anti PJP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections (Category 2B recommendation)
i 
Diarrhea/ Colitis Any Grade General Guidance For Any Grade: 
- Monitor for symptoms that may be related to 
diarrhea/enterocolitis (abdominal pain, cramping, or 
changes in bowel habits such as increased frequency over 
baseline or blood in stool) or related to bowel perforation (such as sepsis, peritoneal signs and ileus). 
- Patients should be thoroughly evaluated to rule out any 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 28 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
alternative etiology (e.g., disease progression, other 
medications, or infections) including testing for 
clostridium difficile toxin, etc. 
- Steroids should be considered in the absence of clear 
alternative etiology, even for low grade events, in order to 
prevent potential progression to higher grade event. 
- Use analgesics carefully; they can mask symptoms of 
perforation and peritonitis.
Grade 1 
(Diarrhea: stool 
frequency of <4 per day over baseline)  (Colitis: asymptomatic; clinical or diagnostic 
observations only) No dose modifications. For Grade 1 :  
- Close monitoring for worsening symptoms 
- Consider symptomatic treat ment including hydration, 
electrolyte replacement, die tary changes (e.g., American 
Dietetic Association colitis diet), and loperamide. Use of probiotics as per treating physician’s clinical judgment. 
Grade 2  
(Diarrhea: stool 
frequency of 4-6 per day over baseline)  (Colitis: abdominal pain; mucus or blood 
in stool) Hold study drug/study regimen until 
resolution to ≤ Grade 1 
• If toxicity worsens then treat as 
Grade 3 or Grade 4. 
• If toxicity improves to ≤ Grade 1 
then study drug/study regimen can 
be resumed after completion of 
steroid taper. For Grade 2 :  
- Consider symptomatic treat ment including hydration, 
electrolyte replacement, die tary changes (e.g., American 
Dietetic Association colitis diet), and loperamide and/or budesonide.  
- Promptly start prednisone 1  to 2 mg/kg/day PO or IV 
equivalent.  
- If event is not responsive within 3-5 days or worsens 
despite prednisone at 1 to  2 mg/kg/day PO or IV 
equivalent, GI consult should be obtained for consideration of further workup such as imaging and/or 
colonoscopy to confirm colitis  and rule out perforation, 
and prompt treatment with IV methylprednisolone 2 to 4 mg/kg/day started.  
- If still no improvement within 3-5 days despite 2 to 4 
mg/kg IV methylprednisolone, promptly start 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 29 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
immunosuppressives such as in fliximab at 5 mg/kg once 
every 2 weeksi. Caution : It is important to rule out bowel 
perforation and refer to infliximab label for general 
guidance before using infliximab.   
- Consider, as necessary, di scussing with study sponsor-
investigator (via the Big Ten CRC project manager) if no resolution to ≤ Grade 1 in 3-4 days. 
- Once improving, gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungals and anti 
PJP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
i.
Grade 3 or 4  
 (Grade 3 diarrhea: 
stool frequency of ≥7 
per day over baseline)  (Grade 4 diarrhea: 
life threatening 
consequences)  (Grade 3 colitis: severe abdominal pain, change in 
bowel habits, 
medical intervention indicated, peritoneal signs; Grade 4 colitis: life-
threatening Grade 3 
Permanently discontinue study drug/study regimen if toxicity does not 
improve to Grade ≤1 within 14 days; 
study drug/study regimen can be resumed after completion of steroid taper. 
 
Grade 4 
Permanently discontinue study drug/study regimen. For Grade 3 or 4: 
- Promptly initiate empiric IV methylprednisolone 2 to 4 
mg/kg/day or equivalent.  
- Monitor stool frequency and volume and maintain 
hydration.   
- Urgent GI consult and imaging and/or colonoscopy as 
appropriate. If still no improvement within 3-5 days of IV 
methylprednisolone 2 to 4 mg/kg/day or equivalent, 
promptly start further immunosuppressives (eg infliximab at 5 mg/kg once every 2 weeks). Caution : Ensure GI 
consult to rule out bowel perforation and refer to infliximab label for general guidance before using infliximab.  
- Once improving, gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungals and anti-
PJP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
i. 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 30 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
consequences, urgent 
intervention 
indicated) 
Hepatitis 
(Elevated LFTs) 
Infliximab should 
not be used for 
management of 
immune-related 
hepatitis  
 Any Grade General Guidance For Any Grade: 
- Monitor and evaluate liver function test: AST, ALT, ALP 
and total bilirubin (T bili) 
- Evaluate for alternative etio logies (e.g., viral hepatitis, 
disease progression, concomitant medications) 
Grade 1  
(AST or ALT > ULN 
and ≤ to 3 × ULN and/or T bili > ULN < 
1.5 × ULN)
 No dose modification 
If it worsens, treat  as Grade 2 event For Grade 1 
- Continue LFT monitoring per protocol   
Grade 2  
(AST or ALT > 3 to 5 
× ULN and/or T 
bili >1.5- 3.0 × ULN)Hold Study drug/study regimen dose 
until grade 2 resolution to ≤ Grade 1 • If toxicity worsens then treat as 
Grade 3 or Grade 4. 
• If improves to ≤ Grade 1 or baseline 
then resume study drug/study 
regimen after completion of steroid 
taper. For Grade 2:  
- Regular and frequent checking of LFTs (e.g. every 1-2 
days) until elevations of th ese are improving or resolved.   
- If no resolution to ≤ Grade 1 in 1-2 days, consider, as 
necessary, discussing with sponsor-investigator (via the Big Ten CRC project manager). 
- If event is persistent (> 3-5  days) or worsens, promptly 
start prednisone 1 to 2 mg/ kg/day PO or IV equivalent.  
- If still no improvement within 3-5 days despite 1 to 2 
mg/kg/day of prednisone PO or IV equivalent, consider 
additional workup and prompt treatment with IV 
methylprednisolone 2 to 4 mg/kg/day. 
- If still no improvement within 3-5 days despite 2 to 4 
mg/kg/day of IV methylprednisolone, promptly start immunosuppressives (i.e., mycophenolate mofetil)
i. 
Discuss with sponsor-investigator (via the Big Ten CRC project manage
r) if mycophenolate mofetil is not available.  PLEASE SEE 
shaded area 
immediately 
below this section 
to find guidance 
for management 
of “Hepatitis 
(elevated LFTS)” 
in HCC patients  
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 31 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
Infliximab should NOT be used . 
- Once improving, gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungals and anti 
PJP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
i. 
Grade 3 or 4 (Grade 3: AST or ALT >5-20 
× ULN 
and/or T bili > 3.0-10 
× ULN) 
 
Grade 4  (AST or ALT > 20 
× 
ULN and/or T bili > 10 
× ULN) 
  For Grade 3 : 
For elevations in transaminases ≤ 8 × ULN, or elevations in bilirubin ≤ 5 × ULN:  
- -Hold study drug/study regimen 
dose until resolution to ≤ Grade 1 or 
baseline   
- -Resume study drug/study regimen 
if elevations downgrade ≤ Grade 1 or baseline within 14 days and after 
completion of steroid taper 
- Permanently discontinue study 
drug/study regimen if the elevations do not downgrade to ≤ Grade 1 or baseline within 14 days  
For elevations in transaminases > 8 × 
ULN or elevations in bilirubin > 5 × 
ULN, discontinue study drug/study regimen.  Permanently discontinue study drug/study regimen for any case 
meeting Hy’s law criteria (AST and /or 
ALT > 3
× ULN + bilirubin > 2 × ULN 
without initial findings of cholestasis For Grade 3 or 4: 
- Promptly initiate empiric IV m ethylprednisolone at 1 to 4 
mg/kg/day or equivalent.  
- If still no improvement within 3-5 days despite 1 to 4 
mg/kg/day methylprednisolone IV or equivalent, promptly 
start treatment with immunosuppressive therapy 
(mycophenolate mofetil).  Di scuss with study sponsor-
investigator (via the Big Ten CRC project manager) if mycophenolate is not available. Infliximab should NOT 
be used.  
- Hepatology consult, abdominal workup, and imaging as 
appropriate. 
- Once improving, gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungals and anti 
PJP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B 
recommendation])
i. 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 32 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
(i.e. elevated alkaline phos) and in the 
absence of any alternative causeii
For Grade 4:  Permanently discontinue study 
drug/study regimen.  
Hepatitis 
(elevated LFTs) 
Infliximab should 
not be used for 
management of 
immune-related 
hepatitis.   
See instructions at 
bottom of shaded 
area if 
transaminase rise is 
not isolated but (at 
any time) occurs in 
setting of either 
increasing bilirubin 
or signs of 
DILI/liver 
decompensation  Any Grade General Guidance  For Any Grade: 
- Monitor and evaluate liver function test: AST, ALT, ALP, 
and TB. 
- Evaluate for alternative etio logies (e.g., viral hepatitis, 
disease progression, concomitant medications, worsening 
of liver cirrhosis [e.g., portal vein thrombosis]). 
- For HBV+ patients: evaluate quantitative HBV viral load, 
quantitative HBsAg, or HBeAg 
- For HCV+ patients: evaluate quantitative HCV viral load 
- Consider consulting hepatologist/Infectious disease 
specialist regarding change/im plementation in/of antiviral 
medications for any patient w ith an elevated HBV viral 
load >2000 IU/ml 
- Consider consulting hepatologist/Infectious disease 
specialist regarding change/im plementation in/of antiviral 
HCV medications if HCV viral load increased by ≥2-fold 
For HCV+ with HBcAB+: Evaluate for both HBV and HCV as 
above  THIS shaded 
area is guidance 
only for 
management of 
“Hepatitis 
(elevated LFTs)” 
in HCC patients   
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 33 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
 Grade 1 
(Isolated AST or 
ALT >ULN and 
≤5.0×ULN, whether 
normal or elevated at 
baseline)   No dose modifications. 
 If ALT/AST elevations represents 
significant worsening based on 
investigator assessment, then treat as 
Grade 2 event. 
For all grades, see instructions at bottom 
of shaded area if transaminase rise is not 
isolated but (at any time) occurs in 
setting of either increasing bilirubin or 
signs of DILI/liver decompensation 
 Grade 2 
(Isolated AST or 
ALT >5.0×ULN and 
≤8.0×ULN, if normal 
at baseline) 
 
(Isolated AST or ALT 
>2.0×baseline and 
≤12.5×ULN, if 
elevated >ULN at 
baseline)   Hold study drug/study regimen dose 
until Grade 2 resolution to Grade ≤1 
or baseline. 
 If toxicity worsens, then treat as 
Grade 3 or Grade 4. 
If toxicity improves to Grade ≤1 or 
baseline, resume study drug/study 
regimen after completion of steroid 
taper. For Grade 2: 
- Regular and frequent checking of LFTs (e.g., every 1 to 3 
days) until elevations of th ese are improving or resolved. 
- Recommend consult hepatol ogist; consider abdominal 
ultrasound, including Doppler assessment of liver 
perfusion. 
- Consider, as necessary, discussing with study physician. 
- If event is persistent (>3 to 5 days) or worsens, and 
investigator suspects toxic ity to be immune-mediated AE, 
recommend to start prednisone  1 to 2 mg/kg/day PO or IV 
equivalent. 
- If still no improvement within  3 to 5 days despite 1 to 
2 mg/kg/day of prednisone PO or IV equivalent, consider 
additional workup and treatment with IV 
methylprednisolone 2 to 4 mg/kg/day. 
If still no improvement within  3 to 5 days despite 2 to 
4 mg/kg/day of IV methylpre dnisolone, consider additional 
abdominal workup (including liver  biopsy) and imaging (i.e., 
liver ultrasound), and consider  starting immunosuppressives 
(i.e., mycophenolate mofetil).a Discuss with study physician if 
mycophenolate mofetil is not available. Infliximab should 
NOT be used. 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 34 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
 Grade 3 
(Isolated AST or 
ALT >8.0×ULN and 
≤20.0×ULN, if 
normal at baseline) 
 
(Isolated AST or 
ALT >12.5×ULN 
and ≤20.0×ULN, if  
elevated >ULN at 
baseline)   Hold study drug/study regimen dose 
until resolution to Grade ≤1 or 
baseline 
 Resume study drug/study regimen if 
elevations downgrade to Grade ≤1 or 
baseline within 14 days and after 
completion of steroid taper. 
 Permanently discontinue study 
drug/study regimen if the elevations 
do not downgrade to Grade ≤1 or 
baseline within 14 days 
 Permanently discontinue study 
drug/study regimen for any case 
meeting Hy’s law criteria, in the 
absence of any alternative cause.b For Grade 3: 
- Regular and frequent checking of LFTs (e.g., every 1-2 
days) until elevations of th ese are improving or resolved. 
- Consult hepatologist (unless investigator is hepatologist); 
obtain abdominal ultrasound, including Doppler 
assessment of liver perfusion; a nd consider liver biopsy. 
- Consider, as necessary, discussing with study physician. 
- If investigator suspects toxicity to be immune-mediated, 
promptly initiate empiric IV  methylprednisolone at 1 to 
4 mg/kg/day or equivalent. 
- If no improvement within 3 to 5 days despite 1 to 
4 mg/kg/day methylprednisol one IV or equivalent, obtain 
liver biopsy (if it has not been done already) and promptly 
start treatment with immunosuppressive therapy 
(mycophenolate mofetil). Discuss with study physician if 
mycophenolate is not available. Infliximab should NOT 
be used.  
Once the patient is improving, gradually taper steroids over 
≥28 days and consider prophylac tic antibiotics, antifungals, 
and anti-PCP treatment (refer to current NCCN guidelines for 
treatment of cancer-related infections [Category 2B 
recommendation]).i 
 Grade 4 
(Isolated AST or 
ALT >20×ULN,  
whether normal or 
elevated at baseline)   
 Permanently discontinue study 
drug/study regimen. For Grade 4: 
Same as above  
(except would recommend obtaining liver biopsy early)  
If transaminase rise is not iso lated but (at any time) occurs i n setting of either increasing total/direct bilirubin (≥1.5×ULN , if normal at 
baseline; or 2×baseline, if >ULN  at baseline) or signs of DILI/ liver decompensation (e.g., fever, elevated INR): 
- Manage dosing for Grade 1 tran saminase rise as instructed for G rade 2 transaminase rise 
- Manage dosing for Grade 2 tran saminase rise as instructed for G rade 3 transaminase rise 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 35 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
- Grade 3-4: Permanently discontinue study drug/study regimen  
Nephritis or 
Renal Dysfunction (Elevated Serum Creatinine)  Any Grade  General Guidance For Any Grade: 
- Consult with Nephrologist 
- Monitor for signs and symptoms that may be related to 
changes in renal function (e.g. routine urinalysis, elevated serum BUN and creatinine, decr eased creatinine clearance, 
electrolyte imbalance, decrease in urine output, or 
proteinuria).  
- Patients should be thoroughly evaluated to rule out any 
alternative etiology (e.g., disease progression or infections). 
- Steroids should be considered in the absence of clear 
alternative etiology even for low grade events (Grade 2), in 
order to prevent potential progression to higher grade 
event.
Grade 1 (Serum Creatinine > 1-1.5
× baseline; > 
ULN to 1.5 × ULN) No dose modifications. For Grade 1 :  
- Monitor serum creatinine weekly and any accompanying 
symptoms. 
 If creatinine returns to base line, resume its regular 
monitoring per study protocol. 
 If it worsens, depending on the severity, treat as Grade 
2 or Grade 3 or 4.  
- Consider symptomatic treat ment including hydration, 
electrolyte replacement, and diuretics. 
Grade 2 (Serum Creatinine>1.5-3.0
× 
baseline; >1.5-
3.0×ULN) 
 Hold study drug/study regimen until 
resolution to ≤ Grade 1 or baseline. • If toxicity worsens then treat as 
Grade 3 or Grade 4. 
• If toxicity improves to ≤ Grade 1 or 
baseline then resume study For Grade 2 :  
- Consider symptomatic treat ment including hydration, 
electrolyte replacement, and diuretics.  
- Carefully monitor serum crea tinine every 2-3 days and as 
clinically warranted. 
- Consult Nephrologist and consider renal biopsy if 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 36 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
drug/study regimen after completion 
of steroid taper. clinically indicated. 
- If event is persistent (> 3-5  days) or worsens, promptly 
start prednisone 1 to 2 mg/ kg/day PO or IV equivalent.  
- If event is not responsive within 3-5 days or worsens 
despite prednisone at 1 to  2 mg/kg/day PO or IV 
equivalent, additional wor kup should be considered and 
prompt treatment with IV methylprednisolone at 2 to 4 mg/kg/day started.  
- Once improving gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungals and anti 
PJP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
i.  
- When event returns to baseline, resume study drug/study 
regimen and routine serum creatinine monitoring per study protocol.
Grade 3 or 4  (Grade 3:  serum creatinine > 3.0 
× 
baseline; >3.0-6.0 × 
ULN; 
 Grade 4: serum creatinine > 6.0 
× 
ULN)  Permanently discontinue study 
drug/study regimen For Grade 3 or 4 : 
- Carefully monitor serum cr eatinine on daily basis. 
- Consult Nephrologist and consider renal biopsy if 
clinically indicated. 
- Promptly start prednisone 1  to 2 mg/kg/day PO or IV 
equivalent.  
- If event is not responsive within 3-5 days or worsens 
despite prednisone at 1 to  2 mg/kg/day PO or IV 
equivalent, additional wor kup should be considered and 
prompt treatment with IV methylprednisolone 2 to 4 
mg/kg/day started.  
- Once improving, gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungals and anti 
PJP treatment (please refer to current  NCCN guidelines for treatment of  cancer-related infections [Category 2B 
recommendation])
i
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 37 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
Rash 
(excluding 
Bullous skin 
formations) Any Grade 
(refer to NCI CTCAE 
v 4 for definition of severity/grade 
depending on type of 
skin rash)
 General Guidance For Any Grade : 
- Monitor for signs and symptoms of dermatitis (rash and 
pruritus).  
- **IF THERE IS ANY BULLOUS FORMATION, THE 
STUDY SPONSOR-INVESTIGATOR SHOULD BE CONTACTED AND STUDY DRUG 
DISCONTINUED **
Grade 1  No dose modification For Grade 1 : 
- Consider symptomatic tr eatment including oral 
antipruritics (e.g., diphenhydr amine or hydroxyzine) and 
topical therapy (e.g., urea cream). 
Grade 2 For persistent (> 1- 2 weeks) Grade 2 
events, hold scheduled study drug/study 
regimen until resolution to ≤ Grade 1 or 
baseline  
 If toxicity worsens then treat as 
Grade 3.  
 If toxicity improves Grade ≤1 or 
baseline, then resume drug/study regimen after completion of steroid taper. For Grade 2 : 
- Obtain dermatology consult.  
- Consider symptomatic tr eatment including oral 
antipruritics (e.g., diphenhydr amine or hydroxyzine) and 
topical therapy (e.g., urea cream). 
- Consider moderate-stre ngth topical steroid.  
- If no improvement of rash/skin lesions occurs within 3-5 
days or is worsening despite symptomatic treatment and/or 
use of moderate strength topical steroid. Consider, as 
necessary, discussing with sponsor-investigator (via the Big Ten CRC project manager) and promptly start systemic steroids prednisone 1 to 2 mg/kg/day or IV equivalent.   
- Consider skin biopsy if persistent for >1-2 weeks or 
recurs.
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 38 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
Grade 3 or 4  For Grade 3 : 
Hold study drug/study regimen until 
resolution to ≤ Grade 1 or baseline. 
If temporarily holding the study drug/study regimen does not provide improvement of the Grade 3 skin rash to ≤ Grade 1 or baseline within 30 days, then permanently discontinue Study 
drug/study regimen.  
 For Grade 4 : 
Permanently discontinue study drug/study regimen. For Grade 3 or 4 : 
- Consult dermatology  
- Promptly initiate empiric IV methylprednisolone 1 to 4 
mg/kg/day or equivalent.  
- Consider hospitalization. 
- Monitor extent of rash [Rule of Nines]. 
- Consider skin biopsy (preferabl y more than 1) as clinically 
feasible. 
- Once improving, gradually taper steroids over ≥28 days 
and consider prophylactic an tibiotics, antifungals and anti 
PJP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
i 
- Consider, as necessary, di scussing with study sponsor-
investigator (via the Big Ten CRC project manager). 
Endocrinopathy 
(e.g., hyperthyroidism, hypothyroidism, 
hypopituitarism, 
and adrenal insufficiency
 
Type 1 diabetes mellitus, hypophysitis, 
exocrine event of 
amylase/lipase increased also included in this section) Any Grade  
(depending on the 
type of 
endocrinopathy, refer to NCI CTCAE v4 for defining the CTC grade/severity) General Guidance For Any Grade : 
- Consider consulting an endocrinologist for endocrine 
events. 
- Consider, as necessary, di scussing with study sponsor-
investigator (via the Big Ten CRC project manager). 
- Monitor patients for signs and symptoms of 
endocrinopathies.  Non-specific symptoms include headache, fatigue, behavior changes, changed mental 
status, vertigo, abdominal pain, unusual bowel habits, 
hypotension polydipsia, polyuria and weakness. 
- Patients should be thoroughly evaluated to rule out any 
alternative etiology (e.g ., disease progression including 
brain metastases, or infections). 
- Depending on the suspected e ndocrinopathy monitor and 
evaluate thyroid function tests: TSH, free T
3 and free T 4 
and other relevant endocrine a nd related labs (e.g., blood 
glucose and ketone levels, HgA1c).
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 39 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
- For modest asymptomatic ele vations in serum amylase and 
lipase, corticosteroid treatment is not indicated as long as 
there are no other signs or symptoms of pancreatic 
inflammation.  
- If a patient experiences an AE that is thought to be 
possibly of autoimmune nature (e.g., thyroiditis, pancreatitis, hypophysitis, di abetes insipidus), the 
investigator should send a blood sample for appropriate 
autoimmune antibody testing 
Grade 1  No dose modifications. For Grade 1 : (including those with asymptomatic TSH 
elevation) 
- Monitor patient with appropriate endocrine function tests. 
- For suspected hypophysitis/ hypopituitarism, consider 
consultation of an endocrinol ogist to guide assessment of 
early-morning ACTH, cortisol, TSH and free T4; also 
consider gonadotropins, sex hormones, and prolactin 
levels, as well as cosyntropin stimulation test (though it may not be useful in diagnosing early secondary adrenal insufficiency). 
- If TSH < 0.5
× LLN, or TSH >2 × ULN or consistently out 
of range in 2 subsequent m easurements, include free T 4 at 
subsequent cycles as clinically indicated and consider endocrinology consult.
Grade 2  For Grade 2 endocrinopathy other than 
hypothyroidism  and Type 1 diabetes 
mellitus, hold study drug/study regimen dose until subject is clinically stable. 
 If toxicity worsens then treat as 
Grade 3 or Grade 4  
Study drug/study regimen can be resumed once event stabilizes and after completion of steroid taper.For Grade 2 : (including those with symptomatic 
endocrinopathy) 
- Consult endocrinologist to gui de evaluation of endocrine 
function and, as indicated by suspected endocrinopathy 
and as clinically indicated, consider pituitary scan. 
- Isolated hypothyroidism may be treated with replacement 
therapy without treatment interruption and without corticosteroids. 
- Isolated Type 1 diabetes mellitus (DM) may be treated 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 40 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
Patients with endocrinopathies who may 
require prolonged or continued steroid 
replacement (e.g. adrenal insufficiency) 
can be retreated with study drug/study regimen on the following conditions: 
1. The event stabilizes and is 
controlled. 
2. The patient is clinically stable as 
per investigator or treating 
physician’s clinical judgement. 
3. Doses of prednisone are 
≤10 mg/day or equivalent.  with appropriate diabetic the rapy, without study drug/study 
regimen interruption, and without corticosteroids. 
- For all patients with abnorma l endocrine work up, except 
for those with isolated hypothyroidism, or Type I DM, and as guided by endocrinologist, consider short-term, corticosteroids (e.g., 1-2 mg/kg/day methylprednisolone or IV equivalent) and prompt i nitiation of treatment with 
relevant hormone replacement (e.g. hydrocortisone, or sex 
hormones). 
- Once patients on steroids are improving, gradually taper 
immunosuppressive steroids ( as appropriate and with 
guidance of endocrinologist) ove r ≥28 days and consider 
prophylactic antibiotics, antif ungals and anti PJP treatment 
(please refer to current NCCN guidelines for treatment of 
cancer-related infections [Ca tegory 2B recommendation])
i 
- For patients with normal endocrine work up (lab or MRI 
scans), repeat labs/MRI as clinically indicated.
Grade 3 or 4  For Grade 3 or 4 endocrinopathy other 
than hypothyroidism  and Type 1 
diabetes mellitus, hold study drug/study 
regimen dose until endocrinopathy 
symptom(s) are controlled Resume study drug/study regimen administration once event stabilizes and after completion of steroid taper.  
Patients with endocrinopathies who 
may require prolonged or continued steroid replacement (e.g., adrenal insufficiency) can be retreated with study drug/study regimen on the 
following conditions:For Grade 3 or 4: 
- Consult endocrinologist
 to guide evaluation of endocrine 
function and, as indicated by suspected endocrinopathy 
and as clinically indicated, consider pituitary scan. 
Hospitalization recommended. 
- For all patients with abnorma l endocrine work up, except 
those with isolated hypothyroidism or Type 1 DM, and as guided by an endocrinologist, promptly initiate empiric IV methylprednisolone 1 to 2 mg /kg/day or equivalent, as well 
as relevant hormone replaceme nt (e.g., hydrocortisone, sex 
hormones). 
- Isolated hypothyroidism may be treated with replacement 
therapy without treatment interruption and without corticosteroids 
- Isolated Type 1 diabetes mellitus may be treated with 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 41 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
1. The event stabilizes and is 
controlled. 
2. The patient is clinically stable as per 
investigator or treating physician’s clinical judgement. 
3.   Doses of prednisone are ≤10 mg/day 
or equivalent. appropriate diabetic thera py, without study drug/study 
regimen interruption, and without corticosteroids. 
- For adrenal crisis, severe dehydration, hypotension, or 
shock: immediately initiate i ntravenous corticosteroids 
with mineralocorticoid activity. 
- Once patients on steroids are improving, gradually taper 
immunosuppressive steroids ( as appropriate and with 
guidance of endocrinologist) ove r ≥28 days and consider 
prophylactic antibiotics, antif ungals and anti PJP treatment 
(please refer to current NCCN guidelines for treatment of cance
r-related infections [Cate gory 2B recommendation])i
Neurotoxicity  
(includes but not limited to limbic encephalitis. 
autonomic 
neuropathy, excluding Myasthenia Gravis and 
Guillain-Barre) Any Grade  
 (Please refer to CTCAE v 4 for 
definition of 
severity/grade depending on type of neurotoxicity) General Guidance - Patients should be evaluated t o rule out any alternative 
etiology (e.g., disease progressi on, infections, metabolic 
syndromes or medications).  
- Monitor patient for general s ymptoms (headache, nausea, 
vertigo, behavior change, or weakness). 
- Consider appropriate d iagnostic testing (e.g. 
electromyogram and nerve conduction investigations). 
- Symptomatic treatment with neurological consult as 
appropriate. 
Grade 1 No dose modifications For Grade 1: 
- See “Any Grade” recommendations above. 
Grade 2  For acute motor neuropathies or 
neurotoxicity, hold study drug/study regimen dose until resolution to ≤ Grade 1 
 For sensory neuropathy/neuropathic 
pain, consider holding study 
drug/study regimen dose until 
resolution to ≤ Grade 1. 
o If toxicity worsens then treat as - Consider, as necessary, discu ssing with the study sponsor-
investigator (via the Big Ten CRC project manager). 
- Obtain neurology consult  
- Sensory neuropathy/neuropat hic pain may be managed by 
appropriate medications (e.g ., gabapentin or duloxetine). 
- Promptly start systemic st eroids prednisone 1 to 2 
mg/kg/day PO or IV equivalent.  
- If no improvement within 3-5 days despite 1 to 2 
mg/kg/day prednisone PO or  IV equivalent, consider 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 42 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
Grade 3 or Grade 4  
 Study drug/study regimen can be 
resumed once event improves to 
Grade ≤1 and after completion of 
steroid taper.additional workup and prom ptly treat with additional 
immunosuppressive therapy (e.g. IVIgG).  
 
 Grade 3 or 4 
 For Grade 3: 
 Hold Study drug/study regimen dose 
until resolution to ≤ Grade 1. 
 Permanently discontinue study 
drug/study regimen if Grade 3 imAE does not resolve to ≤ Grade 1 within 30 days. 
 
For Grade 4: Permanently discontinue study drug/study regimen For Grade 3 or 4 : 
- Consider, as necessary, di scussing with study sponsor-
investigator (via the Big Ten CRC project manager). 
- Obtain neurology consult. 
- Consider hospitalization. 
- Promptly initiate empiric IV methylprednisolone 1 to 2 
mg/kg/day or equivalent.  
- If no improvement within 3-5 days despite IV 
corticosteroids, consider add itional workup and promptly 
treat with additional immunosuppressants (e.g. IV IG).  
- Once stable, gradually taper steroids over ≥28 days. 
Peripheral 
neuromotor syndromes (such as Guillain-Barre and 
Myasthenia 
Gravis) Any Grade General Guidance For Any Grade: 
- The prompt diagnosis of i mmune-mediated peripheral 
neuromotor syndromes is impor tant, since certain patients 
may unpredictably experien ce acute decompensations 
which can result in substantia l morbidity or in the worst 
case, death. Special care should be taken for certain 
sentinel symptoms which may predict a more severe outcome, such as prominent dysphagia, rapidly progressive weakness, and signs of respiratory insufficiency or au tonomic instability. 
- Patients should be evaluated t o rule out any alternative 
etiology (e.g., disease progressi on, infections, metabolic 
syndromes or medications). I t should be noted that the 
diagnosis of immune-mediate d peripheral neuromotor 
syndromes can be particularly c hallenging in patients with 
underlying cancer, due to the multiple potential 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 43 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
confounding effects of cancer (and its treatments) 
throughout the neuraxis. Given the importance of prompt 
and accurate diagnosis, it is  essential to have a low 
threshold to obtain a neurological consult 
- Neurophysiologic diagnostic t esting (e.g., electromyogram 
and nerve conduction inves tigations, and “repetitive 
stimulation” if myasthenia is suspected) are routinely indicated upon suspicion of  such conditions and may be 
best facilitated by means of a  neurology consultation.  
- It is important to consider tha t the use of steroids as the 
primary treatment of Guillain-Barre is not typically considered effective. Patie nts requiring treatment should 
be started with IV IG and fo llowed by plasmapheresis if 
not 
responsive to IVIG.
Grade 1 No dose modification For Grade 1 : 
- Consider, as necessary, discu ssing with the study sponsor-
investigator (via the Big Ten CRC project manager). 
- Care should be taken to monitor patients for sentinel 
symptoms of a potential d ecompensation as described 
above. 
- Obtain a neurology consult 
Grade 2 Hold study drug/study regimen dose 
until resolution to ≤ Grade 1. 
Permanently discontinue study drug/study regimen if it does not resolve to ≤ Grade 1 within 30 days or if there 
are signs of respiratory insufficiency or 
autonomic instability.  Grade 2  
- Consider, as necessary, discu ssing with the study sponsor-
investigator (via the Big Ten CRC project manager).  
- Care should be taken to monitor patients for sentinel 
symptoms of a potential d ecompensation as described 
above. 
- Obtain a neurology consult.  
- Sensory neuropathy/neuropat hic pain may be managed by 
appropriate medications (e.g ., gabapentin or duloxetine). 
MYASTHENIA GRAVIS o Steroids may be successfully used to 
treat Myasthenia 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 44 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
Gravis. Important to consider that steroid therapy 
(especially with high doses) may result in transient 
worsening of myasthenia and should typically be 
administered in a monitored setting under supervision of a consulting neurologist. 
o Patients unable to tolerate steroids may be candidates 
for treatment with plasmapheresis or IVIG. Such decisions are best made in consultation with a 
neurologist, taking into account the unique needs of 
each patient. 
o If Myasthenia Gravis-like neurotoxicity is present, 
consider starting acetylcholine esterase (AChE) inhibitor therapy in addition to steroids. Such therapy, 
if successful, can also serve t o reinforce the diagnosis. 
GUILLAIN-BARRE:  o It is important to consider here that the use of steroids 
as the primary treatment of Guillain-Barre is not typically considered effective.  
o Patients requiring treatment should be started with 
IVIG and followed by plasmapheresis if not responsive to IVIG.
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 45 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
Grade 3 or 4 For Grade 3 : 
Hold study drug/study regimen dose 
until resolution to ≤ Grade 1 
Permanently discontinue study drug/study regimen if Grade 3 imAE does not resolve to ≤ Grade 1 within 30 days or if there are signs of respiratory insufficiency or au tonomic instability. 
 
For Grade 4 : 
Permanently discontinue study drug/study regimen For Grade 3 or 4  (severe or life threatening events):  
- Consider, as necessary, di scussing with study sponsor-
investigator (via the Big Ten CRC project manager). 
- Recommend hospitalization. 
- Monitor symptoms and obtain neurological consult. 
MYASTHENIA GRAVIS o Steroids may be successfully  used to treat Myasthenia 
Gravis.  It should typically be administered in a monitored 
setting under supervision of a  consulting neurologist. 
o Patients unable to tolerate steroids may be candidates for 
treatment with plasmapharesis or IVIG. 
o If Myasthenia Gravis-like neurotoxicity present, consider 
starting acetylcholine esterase (AChE) inhibitor therapy in 
addition to steroids. Such th erapy, if successful, can also 
serve to reinforce the diagnosis. 
GUILLAIN-BARRE :  
o It is important to consider here that the use of steroids as 
the primary treatment of Guillain-Barre is not typically 
considered effective.  
o Patients requiring treatment should be started with IVIG 
and followed by plasmapheresis if not responsive to IVIG. 
Myocarditis  Any Grade General Guidance 
Discontinue drug permanently if biopsy-
proven immune-mediated myocarditis.  For Any Grade: 
- The prompt diagnosis of imm une-mediated myocarditis is 
important, particularly in patients with baseline 
cardiopulmonary disease and reduced cardiac function.  
- Consider, as necessary, discussing with the study 
physician. 
- Monitor patients for signs and symptoms of myocarditis 
(new onset or worsening ch est pain, arrhythmia, shortness 
of breath, peripheral edema). As some symptoms can 
overlap with lung toxicities, s imultaneously evaluate for 
and rule out pulmonary toxicity as well as other causes 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 46 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
(e.g., pulmonary embolism , congestive heart failure, 
malignant pericardial effusion). A Cardiology consultation 
should be obtained early, w ith prompt assessment of 
whether and when to complete a cardiac biopsy, including any other diagnostic procedures. 
- Initial work-up should include clinical evaluation, BNP, 
cardiac enzymes, ECG, echocardiogram (ECHO), monitoring of oxygenation via pulse oximetry (resting and 
exertion), and additional laboratory work-up as indicated. 
Spiral CT or cardiac MRI can complement ECHO to assess wall motion abnormalities when needed. 
Patients should be thoroughly evaluated to rule out any 
alternative etiology (e.g., disease progression, other 
medications, or infections)  
 G r a d e  1  
(asymptomatic with 
laboratory (e.g., BNP) or cardiac imaging abnormalities)  No dose modifications required unless 
clinical suspicion is high, in which case 
hold study drug/study regimen dose during diagnostic work-up for other etiologies. If study drug/study regimen is held, resume after complete resolution to Grade 0.  For Grade 1 (no definitive findings):  
- Monitor and closely follow up in 2 to 4 days for clinical 
symptoms, BNP, cardiac enzymes, ECG, ECHO, pulse oximetry (resting and exertion), and laboratory work-up as clinically indicated. 
Consider using steroids if clinical suspicion is high.  
 Grade 2, 3 or 4 
Grade 2: Symptoms 
with mild to 
moderate activity or exertion  
Grade 3: Severe with 
symptoms at rest or 
with minimal activity or exertion; intervention  If Grade 2 -- Hold study drug/study 
regimen dose until resolution to 
Grade 0. If toxicity rapidly improves 
to Grade 0, then the decision to reinitiate study drug/study regimen will be based upon treating physician’s clinical judgment and 
after completion of steroid taper. If 
toxicity does not rapidly improve, permanently. discontinue study drug/study regimen.For Grade 2-4: 
- Monitor symptoms daily, hospitalize. 
- Promptly start IV methylpredni solone 2 to 4 mg/kg/day or 
equivalent after Cardiology c onsultation has determined 
whether and when to complete diagnostic procedures including a cardiac biopsy. 
- Supportive care (e.g., oxygen). 
- If no improvement within 3 to 5 days despite IV 
methylprednisolone at 2 to 4  mg/kg/day, promptly start 
immunosuppressive therapy such as TNF inhibitors 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 47 of 79 Table 3: Dosing Modification and Toxicity Management Guidelines  for Specific Immune-mediated  Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
Adverse Event Event Grade 
(CTCAE v. 4) Dose Modifications Toxicity Management 
indicated 
 
Grade 4: Life-
threatening 
consequences; urgent intervention indicated (e.g., continuous IV 
therapy or 
mechanical hemodynamic support)  If Grade 3-4, permanently discontinue 
study drug/study regimen. (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is 
important to rule out sepsis and refer to infliximab label 
for general guidance before using infliximab. 
Once the patient is improving, gradually taper steroids over 
≥28 days and consider prophylac tic antibiotics, antifungals, or  
anti-PJP treatment (refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B 
recommendation]).
i 
i: ASCO Educational Book 2015 “Managing Immune Checkpoint Block ing Antibody Side Effects” by Michael Pestow MD. 
ii: FDA Liver Guidance Document 2009 Guidance for Industry: Dru g Induced Liver Injury – Premarketing Clinical Evaluation. 
 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 48 of 79 Table 4.  Dosing Modification and Toxicity Management Guideline s for Infusion-Related Reactio ns for Durvalumab Monotherapy  
(1 November 2017 Version) 
Severity 
Grade Dose Modifications  Toxicity Management  
Any Grade General Guidance For Any Grade: 
- Management per institutional sta ndard at the discretion of inve stigator. 
- Monitor patients for signs and symptoms of infusion-related rea ctions 
(e.g., fever and/or shaking chills , flushing and/or itching, al terations in 
heart rate and blood pressure, dyspnea or chest discomfort, or skin rashes) 
and anaphylaxis (e.g., generali zed urticaria, angioedema, wheez ing, 
hypotension, or tachycardia). 
Grade 1 or 2  For Grade 1:  
The infusion rate of study drug/study regimen may be decreased by 50% or temporarily interrupted until resolution of the event.  For Grade 2: 
The infusion rate of study drug/study regimen may be 
decreased 50% or temporarily interrupted until resolution of the event. 
Subsequent infusions may be given at 50% of the initial 
infusion rate For Grade 1 or Grade 2: 
- Acetaminophen and/or antihistami nes may be administered per 
institutional standard at the di scretion of the investigator.  
- Consider premedication per ins titutional standard prior to subs equent 
doses. 
- Steroids should not be used for routine premedication of Grade ≤2 infusion 
reactions. 
Grade 3 or 4 For Grade 3 or 4:  
Permanently discontinue study drug/study regimen. For Grade 3 or 4: 
- Manage severe infusion-related reactions per institutional stan dards (e.g., 
IM epinephrine, followed by IV d iphenhydramine and ranitidine, and IV 
glucocorticoid). 
 
  
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
         BTCRC-ESO14-012 
09OCT2019  Confidential  Page 49 of 79 Table 5.  Dose Modification and T oxicity Management Guidelines for Non-Immune Mediated Reactions for Durvalumab 
Monotherapy (1 November 2017 Version)  
CTC Grade/ 
Severity Dose Modification Toxicity Management 
Any Grade Note: dose modifications are not r equired for adverse events no t deemed to be related to study 
treatment (i.e. events due to underlying disease) or for labora tory abnormalities not deemed to be 
clinically significant. Treat accordingly as per 
institutional standard 
1 No dose adjustment Treat accordingly as per 
institutional standard 
2 Hold study drug/study regimen un til resolution to ≤ Grade 1 or baseline.  Treat accordingly as per 
institutional standard 
3 Hold study drug/study regimen un til resolution to ≤ Grade 1 or baseline. 
For AEs that downgrade to ≤ Grade 2 within 7 days or resolve to  ≤ Grade 1 or baseline within 
14 days, resume study drug/study regimen administration at next  scheduled dose. Otherwise, 
discontinue study drug/study regimen.  Treat accordingly as per 
institutional standard  
4 Discontinue Study drug/study regime n (Note: for Grade 4 labs, d ecision to discontinue would be 
based on accompanying clinical si gns/symptoms and as per treati ng Investigator’s clinical 
judgment and in consultation w ith the sponsor-investigator.). Treat accordingly as per 
institutional standard 
 
Abbreviations: 
AChE = acetylcholine esterase; AD A = American Dietetic Associat ion; AE = adverse event; ALP = al kaline phosphatase; ALT = alan ine aminotransferase; AST = 
aspartate aminotransferase; CT = computed tomography; GI = gast rointestinal; IDS=Infectious D isease Service; ILD = interstitia l lung disease; IM = intramuscular; 
imAE = immune-mediated adverse event; IV = intravenous; NCI CTC AE = National Cancer Institute C ommon Terminology Criteria for Adverse Events; PO = by 
mouth; TNF = tumor necrosis factor; TSH = thyroid stimulating h ormone; ULN = upper limit of normal.  
 
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
        BTCRC-ESO14-012 
09OCT2019  Confidential  Page 50 of 79 7. STUDY CALENDAR & EVALUATIONS 
Study DayScreen Cycle 1 
Cycle = 28 days Cycles 2-13 30 Days Post 
Treatmen tFollow up 
-28 days Day 1 (-3) Day 1 (±3) 30 days (+7) 
after last doseEvery 3 months 
(±7 da ys)
REQUIR ED ASSESSMENTS 
Informed Consen t X
Diagnosis and Staging1 X
Medical history X
Physical exam and ECOG PS X X X X X
Vital Signs2 X X (x5) X (x3) X
ECG3 X (x3) pre, pos t: C1D1 pre, pos t:C 4 D 1 X
LABORATORY TESTS 
Complete Blood Cell Count (CBC) with diff5XX4XX
Comprehensive Metabolic Profile (CMP), including GGT, 
LDH, magnesium, uric acid6 X X4 X  X   
Amylase, lipase6 X X4X
Urinalysis7 X X4XX
TSH. If TSH abnormal, check free T3, free T4.8X every even cycle 
Prothrombin Time, aPTT, INR9 X
Calculated creatinine clearance X
Serum pregnancy (WOCP)10 -14 days
AEs, imAEs, AESIs & concomitant meds X X X
DISEASE ASSESSMENT5 
CT ches t, abdomen/pelvis X Q 3 months11Q 3 months11
TREATMENT EXPOSURE 
Durvalumab X X
CORRELATIVE STUDIES 
CTC blood sample12 (Indiana University ONLY)- optional Pre-dose pre-dose C4D1 At recu rrence
Archived tissue samples13- mandatory X
Whole blood sample14- mandatory Pre-dose 
BANKING STUDIES 
Whole Blood15– optional X
Unstained Slides (diagnosis and surgery)16- optional X
Serum and Plasma17- optional X X
FOLLOW-UP 
Survival X
Big Ten Cancer Research Consortiu m     Clinical Study Protocol 
        BTCRC-ESO14-012 
09OCT2019  Confidential  Page 51 of 79 Footnotes : 
1: Diagnosis and Staging to incl ude pathology report and TNM st aging 
2: Vital signs to include temperature, blood pressure, pulse ra te, respiratory rate, weight, and height (screen only). 
3: ECGs are required during screening, pre and post treatment o n C1D1, pre and post treatment at C4D1, end of treatment, and a t any other time point when 
clinically indicated. 
4: Cycle 1 Day 1 labs do not need to be repeated if done within  7 days prior to Day 1. 
5: CBC with diff and platelets to  include: hemoglobin, platelet  count, red blood cell count, total white cell count. 
6: CMP to include: albumin, alka line phosphatase, alanine amino transferase (ALT), aspartate aminotransferase (AST), bicarbonat e, calcium, chloride, 
creatinine, gamma glutamyl tran sferase (GGT), glucose, lactate dehydrogenase (LDH), magnesium , potassium, sodium, total biliru bin, total protein, urea or 
blood urea nitrogen (depending on local practice), uric acid. I f total bilirubin is ≥2xULN (a nd no evidence of Gilbert’s syndr ome), fractionate into direct and 
indirect bilirubin. GGT at baselin e and as clinically indicated . Amylase and lipase will be check ed at screening; amylase and/ or lipase (depending on local 
practice) will be checked prior to Day 1 of each cycle. 
7: Urinalysis performed at Screen ing, Day 1 of every cycle, and  as clinically indicated. Urinalysis to include: bilirubin, blo od, glucose, ketones, pH, protein, 
and specific gravity. Microscopy should be used as appropriate to investigate white blood cells  and use the high power field f or red blood cells. 
8: Free T3 and free T4 will only be measured if screening TSH i s abnormal. Free T3 and free T4 should also be measured if ther e is clinical suspicion of an 
adverse event related to  the endocrine system. 
9: Prothrombin time, aPTT and IN R only performed at Screening a nd as clinically indicated. 
10: Pregnancy test: Within 14 days of registration. 
11: Disease assessment will be perfo rmed every 3 months ±7 days  (prior to Cycle 4, 7, 10, etc.) . During follow up, disease ass essment will be performed every 
3 months (±7 days) for up to 1 year from the time of treatment discontinuation (if they have not withdrawn consent). 
12: OPTIONAL - CTC blood samples will be collected at pre-dose Cycle 1 Day 1, pre-dose Cycle 4 Day 1 (3 months), and at the ti me of disease recurrence 
during treatment or follow up.  Please note that CTC blood samp les will only be collected on c onsenting subjects enrolled at t he Indiana University Melvin and 
Bren Simon Cancer Center. 
13: Submission of unstained slides from the subject’s archived initial diagnostic tumor tissue and tissue from the time of sur gery is mandatory (if available).  
See the Correlative Laboratory Manual (CLM) for collection, pro cessing, labeling, and sh ipping instructions. 
14: Mandatory submission of whole blood for gene expression ana lysis is to be collected at Pre-Treatment Cycle 1 Day 1. See CL M for collection, processing, 
labeling, and shipping instructions. 
15: Optional whole blood for banking is to be collected at Pre- Treatment Cycle 1 Day 1. See CL M for collection, processing, la beling, and shipping 
instructions. 
16: Optional unstained slides fo r banking from archived FFPE tu mor blocks from the time of dia gnosis and the time of surgery a re requested (if available). See 
CLM for collection, labeling, and shipping instructions. 
17: Optional serum and plasma for banking are to be collected a t Pre-Treatment Cycle 1 Day 1 and at the 30 Day Post Treatment visit. See CLM for collection, 
labeling, processing, and shipping instructions.
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019 Confidential Page 52 of 79 7.1. Screening 
 
7.1.1.  Within 28 days prior to registration for protocol therapy:  
 Screen for the eligibility for the trial. Patient must satisfy all the inclusion criteria and 
must not have any exclusion criterion. 
 Informed consent 
 Diagnosis and staging: pathol ogy report and TNM staging. 
 Medical history 
 Physical exam and ECOG PS 
 Vital signs: temperature, bl ood pressure, pulse rate, respirato ry rate, weight, and height 
(screen only). 
 12-lead ECG (in triplicate, 2-5 minutes apart). All 12-lead ECG s should be obtained 
after the subject has been resting in a supine position for at least 5 minutes in each 
case. 
 Complete blood count with differen tial (CBC): to include hemogl obin, platelet count, 
red blood cell count, tot al white cell count. 
 Comprehensive metabolic panel (C MP): to include albumin, alkali ne phosphatase, 
alanine aminotransferase, aspar tate aminotransferase, bicarbona te, calcium, chloride, 
creatinine, gamma glu tamyl transferase (GGT), glucose, lactate dehydrogenase, 
magnesium, potassium , sodium, total bilir ubin, total protein, u rea or blood urea 
nitrogen (depending on local pract ice), uric acid. If total bil irubin is ≥2xULN (and no 
evidence of Gilbert’s syndrome), fractionate into direct and in direct bilirubin. GGT at 
baseline and as clin ically indicated. 
 Amylase and lipase 
 Urinalysis: to incl ude bilirubin, blood, gl ucose, ketones, pH, protein, and specific 
gravity. Microscopy should be used a s appropriate to investigat e white blood cells and 
use the high power field  for red blood cells. 
 Thyroid stimulating hormone. Free T3 and free T4 will only be m easured if TSH is 
abnormal. 
 Prothrombin time, aPTT and INR 
 Calculated creatinine clearance using the Cockcroft-Gault formu la or by 24-hour urine 
collection for dete rmination of creatinine clearance. 
 [Within 14 days of registration] S erum pregnancy test for women  of childbearing 
potential (WOCP) 
 Baseline signs and symptoms;  concomitant medications.  
 Baseline CT scan of chest, abdomen and pelvis 
 
7.2. On Treatment 
 
7.2.1.  Cycle 1 Day 1 (or within 3 days prior) : 
 Physical exam and ECOG PS, weight 
 Vital signs: blood pressure and pul se rate will be measured bef ore, during and after the 
infusion at the following tim es (based on a 60-minute infusion) : 
1. At the beginning of the infusi on (at 0 minutes ± 5 minutes) 
2. at 30 minutes after the start  of infusion (± 5 minutes),  
3. at the end of infusion (a t 60 minutes ± 5 minutes) 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 53 of 79 4. at 30 minutes post-infusion (90 minut es from the start of the i nfusion ± 5 minutes) 
5. at 60 minutes post-infusion (120 minut es from the start of the infusion ± 5 minutes) 
o The 1-hour post-infusion observa tion period will apply to the f irst infusion only 
and then for subsequent infusi ons as clinically indicated. 
o If the infusion takes longer th an 60 minutes, blood pressure an d pulse 
measurements should follow the  principles described here (e.g. every 30 minutes), 
or more frequently if c linically indicated.  
 ECG within an hour prior to start  of infusion and at least one time point 0 to 3 hours 
after the infusion. ECGs record ed during the treatment phase wi ll be single tracing. The 
same method of assessment shoul d be used throughout the study. Twelve-lead ECGs 
will be obtained after the subjec t has been resting in a supine  position for at least 5 
minutes in each case.  
 Complete blood count with differential (CBC) 
 Comprehensive metabolic panel (CMP) 
 Amylase and/or lipase (dep ending on local practice) 
 Urinalysis 
 Durvalumab administration 
 Correlative studies:  
o CTC blood sample – optional (pre -dose) (collected only on subje cts enrolled at 
Indiana University) 
o Whole blood- optional 
o Archived tissue samples from di agnosis and surgery (mandatory, if available) 
 Banking studies: 
o Whole blood- optional 
o Unstained slides from archived t umor blocks from diagnosis and surgery - 
(optional, if available) 
o Serum and plasma- optional 
 
Notes:  Cycle 1 Day 1 lab testing need not be repeated if completed wi thin 7 days of starting protocol 
therapy. See CLM for collection, proces sing, labeling and shipping instr uctions. 
 
7.2.2.  
Cycle 2+ Day 1 (±3 days): 
 Physical exam and ECOG PS, weight 
 Vital signs: blood pressure and pul se rate will be measured bef ore, during and after the 
infusion at the following tim es (based on a 60-minute infusion) : 
1. At the beginning of the infusi on (at 0 minutes ± 5 minutes) 
2. at 30 minutes after the start  of infusion (± 5 minutes),  
3. at the end of infusion (a t 60 minutes ± 5 minutes) 
o If the infusion takes longer th an 60 minutes, blood pressure an d pulse 
measurements should follow the  principles described here (e.g. every 30 minutes), 
or more frequently if clinically indicated. 
 Complete blood count with differential (CBC) 
 Comprehensive metabolic panel (CMP) 
 Amylase and/or lipase (dep ending on local practice) 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 54 of 79  Urinalysis 
 Adverse events, immune-related ad verse events, adverse events o f special interest and 
concomitant medications 
 Durvalumab administration 
 Every 3 months (prior to Cycle  4, 7, 10, etc.): CT of chest, ab domen and pelvis 
 Cycle 4 Day 1: (in addition t o procedures listed above) 
o ECG within an hour prior to start  of infusion and at least one time point 0 to 3 
hours after the infusion. ECGs r ecorded during the treatment ph ase will be single 
tracing. The same method of asse ssment should be used throughou t the study. 
Twelve-lead ECGs will be obtained after the subject has been re sting in a supine 
position for at least 5 minutes in each case. 
o Pre-dose C4D1 Correlative studies:  
 CTC blood sample - optional (p re-dose) (collected only on subje cts enrolled at 
Indiana University) 
 
7.3. Protocol therapy discontinuation 
A subject will be discontinue d from the protocol therapy under the following circumstances: 
 Grade ≥ 3 infusion reaction 
 If there is clear evidence of di sease relapse (per RECIST 1.1).  NOTE: If pseudoprogression 
is suspected, a subject will  be allowed to continue durvalumab until biopsy or repeat 
radiographic scans confirm disease relapse.  
 If the treating physician thinks a  change of therapy would be i n the best interest of the 
subject 
 If the subject requests to dis continue protocol therapy 
 If the protocol therapy exhib its unacceptable toxicity 
 If a female subject becomes pregnant  
 If protocol therapy is interrupt ed for ≥ 42 days due to a treat ment-related adverse event.  
 
7.4. Safety Follow-up: 30 days (±7 days)  after last dose of protocol  therapy  
Subjects discontinued from the t reatment phase of the study for  any reason will be evaluated 30 
days (± 7) after the  last dose of study drug or as soon as poss ible thereafter (ex. protocol therapy 
interruption for ≥ 42 days). If a subject is discontinued due t o disease relapse, t he subject will be 
off study after the Safety Fo llow-up visit a nd no further follo w up will be performed. 
 Physical exam and ECOG PS 
 Vital signs: temperature, bl ood pressure, pulse rate, respirato ry rate and weight 
 12-lead ECG. ECG should be obtaine d after the subject has been resting in a supine position 
for at least 5 minutes. The s ame method of assessment should be  used throughout the study. 
 Complete blood count with differential (CBC) 
 Comprehensive metabolic panel (CMP) 
 Urinalysis 
 Adverse events, immune-related ad verse events, adverse events o f special interest and 
concomitant medications 
 Banking studies: 
o Serum and plasma- optional 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 55 of 79 7.5. At Recurrence:  
 Correlative studies:  
o CTC blood sample - optional (c ollected only on s ubjects enrolle d at Indiana University) 
at the time of disease recurrenc e during treatment or follow up . 
 7.6. Follow-up 
Subjects can stop study participa tion at any time. All subjects  without documented disease relapse 
will be followed every 3 months for 1 year from the time of tre atment discontinuation (if they have 
not withdrawn consent) for assessment of survival, disease rela pse, and occurrence of any late AEs.  
 Physical exam and ECOG PS 
 CT scan of the chest and abdomen/ pelvis every 3 months for up to 1 year from the time of 
treatment discontinuation (if t hey have not withdrawn consent).   
 Subjects will be off study after  1 year of follow-up from disco ntinuation of the study drug or at 
documented disease relapse , whichever comes first.  
  8. CRITERIA FOR DISEASE EVALUATION 
 In some circumstances it may be  difficult to distinguish diseas e recurrence and relapse from 
inflammatory findings. It is r ecommended that a repeat disease assessment be performed if needed 
to confirm disease relapse prio r to taking a subject off study.  The disease assessment should be 
performed no sooner than 4 weeks af ter the criteri a for relapse  is first met. During this interim 
period, subjects should continue t o be followed per protocol, i ncluding continued dosing of the 
study drug.  
 8.1. Definitions for Disease E valuation –RECIST version 1.1  [Eur J Ca  45:228-247, 2009]  
 
8.1.1.  Disease Relapse:  
Any clinical or radiographic findi ng(s) that meet  the criteria for measurable or non-
measurable lesions (confirme d by histology/cytology if solitary ) according to RECIST 1.1. 
 If pseudoprogression is  suspected, relapse will be confirmed by  either a biopsy or 
repeat radiographic scans.  
 
8.1.2.  Overall Survival: 
Overall Survival is defined by the  date of registration to date  of death from any cause. 
 
8.1.3.  Relapse Free Survival:  
Time from the date of surgery unt il the criteria for disease re lapse is met or death occurs.  
 
8.2. Methods of Measurement 
 
Both imaging-based evaluation and clinical examination will be used  f or ass essm e nt. The sam e  
imaging modality must be used throughout the study to measure d isease. Baseline imaging should 
be available within 28 days of  the first dose of study drug. 
 8.2.1.  CT and MRI: 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 56 of 79 CT and MRI are the best currently available and most reproducib le imaging methods for assessing 
solid organ malignancy. This guid eline has defined measurabilit y of lesions on CT scan based on 
the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice thickness greater than 
5 mm, the minimum size for a me asurable lesion should be twice the slice thickness.  MRI is also 
acceptable in certain situations (e.g. for body scans).    Use of MRI remains a complex issue.  MRI has excellent contrast , spatial, and temporal resolution; 
however, there are many image a cquisition varia bles involved in  MRI, which greatly impact image 
quality, lesion conspicuity, and measurement.  Furthermore, the  availability of MRI is variable 
globally.  As with CT, if an MRI is performed, the technical sp ecifications of the scanning sequences 
used should be optimized for the  evaluation of the type and sit e of disease.  Furthermore, as with 
CT, the modality used at follow-up should be the same as was us ed at baseline and the lesions should 
be measured/assessed on the same pulse sequence.  It is beyond the scope of the RECIST guidelines 
to prescribe specific MRI pulse s equence parameters for all sca nners, body parts, and diseases.  
Ideally, the same type of scanner should be used and the image acquisition protocol should be 
followed as closely as possible to prior scans.  Body scans sho uld be performed with breath-hold 
scanning techniques, if possible.  PET-CT.  At present, the low dose or attenuation correction CT portion of a combined PET-CT is 
not always of optimal diagnostic CT quality for use with RECIST  measurements.  However, if the 
site can document that the CT performed as part of a PET-CT is of identical diagnostic quality to a 
diagnostic CT (with IV and oral contrast), then the CT portion o f th e P E T -C T  can  b e u s ed  fo r  
RECIST measurements and can be used interchangeably with conven tional CT in accurately 
measuring cancer lesions over time.  Note, however, that the PE T portion of the CT introduces 
additional data, which may bias a n investigator if it is not ro utinely or serially performed.   
 8.2.2.  Chest X-Ray: 
Lesions on chest x-ray are acceptable as measurable lesions whe n they are clearly defined and 
surrounded by an aerated lung ( CT is preferable).   
 8.2.3.  Clinical Examination: 
Clinically detected lesions will only be considered measurable when they are superficial (e.g. skin 
nodules and palpable lymph nodes).   For skin lesions, documenta tion by color photography, 
including a ruler to estimate si ze of the lesion, is recommende d.  Photographs should be retained at 
the institution.  8.2.4.  Cytology and Histology: 
Cytologic and histologic techni ques can be used to confirm dise ase relapse (e.g. detection of an 
enlarged lymph node on imaging, to  differentiate neoplastic fro m reactive etiology).  Cytologic 
confirmation of the neoplastic nature of any effusion that appe ars or worsens during treatment is 
required if the effusion happens t o be the sole suspected site of relapse. 
 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 57 of 79 9. BIOLOGICAL CORRELATIVES  
 9.1 Planned  Correlative Studies:  
 Assessment of changes i n PD-L1 expression with chemoradiotherap y in esophageal cancer and 
correlate with 1 year RFS. 
 Analysis of possible predictive biomarkers of 1 year RFS includ ing PD-L1 expression (at 
diagnosis and in residual diseas e) and tumor infiltrating lymph ocytes (by histology and gene 
expression analysis – by pathwa y analysis and CIBERSORT), both within the tumor and in 
surrounding connective tissue. 
 Assessment of the Immunoscore (ba sed on numeration of lymphocyt e populations - 
CD3/CD45RO, CD3/CD8, CD8/CD45RO – within the center and invasiv e margins of the tumor 
– and correlate it with 1 year RFS 
 Analysis of the correlation between changes in circulating tumo r cell numbers in response to 
PD-L1 inhibition and 1 year RFS in pa tients with residual esoph ageal cancer 
 9.2 Source of Tissue Specimens for Correlative Studies:  
Specimens from the time of initia l diagnosis (archived tissue) and the specimens obtained at the 
time of surgery (residual tumor and any positive lymph node) ar e mandatory (if available) for 
correlative studies.  
 9.3 PD-L1 expression using Tissue Microarrays (31) 
FFPE specimens obtained at the t ime of initial diagnosis as wel l as at the time of surgical 
resection.   
Automated QIF analysis using t he AQUA method utilizing commerci ally availab le antibody.  
 
9.4 Generation of Gene Expression Data 
 
9.4.1 Blood: 
Whole blood will be collected in s tandard BD Vacutainer EDTA tu bes and frozen at -80C. Refer 
to the Correlative Laboratory M anual (CLM) for collection, proc essing, labeling, and shipping 
instructions. 
 
9.4.2 Tumor Specimens: 
Specimens from the time of initia l diagnosis (archived tissue) and the specimens obtained at the 
time of surgery (residual tumor and any positive lymph node) wi ll be submitted by sites to the 
Big Ten CRC biorepository.  Refer  to the CLM for collection, pr ocessing, labeling, and shipping 
instructions.   9.4.3 Sequencing Methods: 
For each sample, DNA & RNA will  be extracted using the Qiagen A ll Prep Universal 
DNA/RNA/miRNA kit (Qiagen, Valen cia CA). Briefly, 100ng of DNA will undergo a highly 
multiplexed PCR reaction to amp lify all exons of 409 genes know n to be mutated in cancer 
(Sanger Gene Census) using the I on Ampliseq Comprehensive Cance r Panel. The Ion Ampliseq 
Comprehensive Cancer Panel is sp ecifically designed for amplifi cation of both formalin-fixed 
paraffin embedded samples as we ll fresh/frozen tissue. Subseque nt to amplification, libraries 
will be sequenced on an Ion Pro ton Sequencer using 200bp fragme nt chemistry and an Ion 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 58 of 79 Proton I chip. An estimated 90 mill ion reads per run will be ge nerated. It is estimated that each 
sample will have 1500-2000X average coverage of each cancer gen e, enabling low allele 
frequency somatic mutation detection. Each sequencing run will be evaluated for technical 
quality control metrics. For bioi nformatics analysis, reads wil l be mapped to the human genome 
using the TMAP algorithm, which i s integrated into the Ion Torr ent Suite Software. After 
mapping, somatic variants will be called (point mutations, inde ls, and copy number variation), 
using the Ion Torrent Variant Cal ler (Life Technologies) and Io n Reporter (Lif e Technologies) 
software packages by identifyi ng those mutations present in the  tumor samples that are absent in 
the germline DNA derived from blood. Annotation of identified v ariants will  be performed by 
cross-referencing the followi ng databases: NIH dbSNP, 1000 geno mes project, COSMIC 
(Catalog of Somatic Mutations i n Cancer), and TCGA (The Cancer Genome Atlas). 
Identification of cance r driver variants, a ssociation with ther apeutic interventions, and 
mutational network analyses will be performed using Ingenuity V ariant Analysis (Ingenuity 
Systems). All data and analyses will be stored on the HIPPA-com pliant Indiana University 
Scholarly Data Archive.  For expression analysis, 10ng of R NA (extracted as described ab ove) will undergo library 
preparation using the Ion Ampliseq  Transcriptome Human Gene Exp ression Kit. This will allow 
for accurate quant itative expression of ~20,000 genes in the hu man genome. Standard workflow 
for gene-level expre ssion will be conducte d using Torrent Suite  Version 5.0. The AmpliSeq 
Transcriptome Plugin tool will be used to generate standard exp ression files.   
 
9.5 Tumor Infiltrating Lymphocytes 
Unstained slide of the specime n obtained at time of diagnosis a nd at the time of surgical resection 
including central area of the t umor and the inva sive margin (32 ).  
 9.6 Immunoscore 
Two regular whole slide FFPE sec tions of the specimen obtained at time of diagnosis and at the 
time of surgical resection (33).  9.7 Optional Sample Banking for Future Studies 
Subject consent will be obtained for additional optional sample s collected for future Big Ten 
Cancer Research Consortium studies . Hoosier Cancer Research Net work, as Administrative 
Headquarters for the Big Ten CRC, will manage the banked sample s. Samples will be banked 
indefinitely in the Hoosier Can cer Research Network Bioreposito ry.  
This includes: 
 Whole blood:  
o Whole blood will be collected prio r to treatment on Cycle 1 Day  1.  
 Pre- and Post-treatment plasma:  
o Whole blood for plasma will be col lected prior to treatment on Cycle 1 Day 1 and at the 
30 Day Post Treatment Visit.  
 Pre- and Post-trea tment serum:  
o Whole blood for serum will be co llected prior to  treatment on C ycle 1 Day 1 and at the 
30 Day Post Treatment Visit. 
 Unstained slides: (If Available) 
o Unstained slides will be obtaine d from the subject’s archived f ormalin fixed paraffin 
embedded tumor blocks from the time of diagnosis and from the s urgical specimen.  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 59 of 79  
Please refer to the CLM for all  sample collection, processing, labeling, and shipping instructions. 
 
 10. DRUG INFORMATION  
 Please refer to the latest ve rsion of the IB, provided as a doc ument separate from this protocol, for 
detailed information on toxicity a ssociated with durvalumab. 
 
10.1. Drug Names:  
MEDI4736, durvalumab  
10.2. Drug Class: 
Durvalumab is a human monoclonal antibody (MAb) of the immunogl obulin G1 kappa (IgG1κ) 
subclass that inhibits binding of  programmed cell death ligand 1 (PD-L1) (B7 homolog 1 [B7-H1], 
cluster of differen tiation [CD]274) to progr ammed cell death 1 (PD-1; CD279) and CD80 (B7-1). 
 
10.3. Formulation, Packaging and Storage 
Durvalumab is formulated at 50 mg/mL in 26 mM histidine/histidi ne-HCl, 275 mM trehalose 
dihydrate, 0.02% (w/v)  polysorbate 80, pH 6.0.  
 The investigational product is  supplied as a vialed liquid solu tion in clear 10R glass vials closed 
with an elastomeric stopper and a flip-off cap overseal. Each v ial contains 500 mg (nominal) of 
active investigational product at  a concentration of 50 mg/mL ( 500 mg/vial). The solution will be 
diluted with 0.9% (w/v) sa line for IV infusion.  
 Investigational product vials are stored at 2°C to 8°C (36°F to  46°F) and must not be frozen. Drug 
product should be kept in secondary packaging until use to prev ent excessive light exposure. 
Durvalumab must be used within t he individually assigned expiry  date on the label. 
 In-use storage and stability 
Total in-use storage time from needle puncture of durvalumab vi al to start of admin istration should 
not exceed 4 hours at room temperature or 24 hours at 2-8°C (36 -46°F). If in-use storage time 
exceeds these limits, a new dose must be prepared from new vial s. Infusion solutions must be 
allowed to equilibrate to room temperature prior to commencemen t of administration. Durvalumab 
does not contain preservativ es and any unused portion must be d iscarded. 
 
10.4. Availability and Distribution 
AstraZeneca/MedImmune will supply durvalumab at no charge to su bjects participating in this 
clinical trial.  
The investigator shall take res ponsibility for and shall take a ll steps to maintain appropriate records 
and ensure appropriate supply, stor age, handling, distribution,  and usage of investigational product 
in accordance with the protocol and any applicable laws and reg ulations. 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 60 of 79 10.5. Preparation  
The dose volume of dur valumab and number of  vials needed for th e subject to achieve the accurate 
dose will be calculated according to the durvalumab dose calcul ation worksheet found in the 
Documents/Info tab of the EDC.  Preparation of infusion bags The preparation of infusion bags  should be done under aseptic c onditions by trained personnel; it 
should not be prepared on the ward. 
 An additional volume of 0.9% (w/v) saline equal to the calculat ed volume of durvalumab to be 
added to the IV bag must be rem oved from the bag prior to addit ion of durvalumab.  
 The calculated volume of durvalumab is then added to the IV bag , and the bag is mixed by gentle 
inversion to ensure homogeneity of the dose in the bag.  Prior to the start of the infusion, ensure that the bag content s are at room temperature to avoid an 
infusion reaction due to the admi nistration of the solution at low temperatures. 
 Vials should be used for speci fic subjects and should not be sh ared between subjects. 
 
10.6. Administration 
Durvalumab will be administered at room temperature (approximat ely 25°C) by controlled infusion 
via an infusion pump int o a peripheral vein. 
 Following preparation of durvalu mab, the entire contents of the  IV bag should be administered as 
an IV infusion over approximately 6 0 minutes (±5 minutes), usin g a 0.2-μm in-line filter.  
 The IV line will be flushed with  a volume of normal saline equa l to the priming volume of the 
infusion set used after the contents of the IV bag are fully ad ministered, or complete the infusion 
according to institutional policy to ensure the full dose is ad ministered and document if the line was 
not flushed.   Since the compatibility of durva lumab with other IV medications  and solutions, other than normal 
saline (0.9% [weight/volume] sod ium chloride for  injection), is  not known, the durvalumab solution 
should not be infused through an IV line in which other solutio ns or medications are being 
administered.  
10.7. Precautions 
Owing to the drug’s mechanism of  action and nonclinical finding s, subjects should be monitored 
for the development of immune-mediated adverse events such as e nterocolitis, dermatitis, 
hepatitis/hepatotoxicity, endocrinopathy, pneumonitis, neuropat hy, serious infection, infusion-
related reactions, anaphylaxis or  serious aller gic reaction, an d immune complex disease.  
 
10.8. Side Effects 
For a comprehensive list of adverse events, please refer to the  current version of the Investigator’s 
Brochure.   
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 61 of 79 Adverse events for durvalumab i nclude but are not limited to ev ents with a potential inflammatory 
or immune-mediated mechanism and w hich may require more frequen t monitoring and/or 
interventions such as steroids , immunosuppressants and/or hormo ne replacement therapy. These 
adverse events are being close ly monitored in clinical studies with durvalumab m onotherapy and 
combination therapy.   The identified risks with durvalu mab monotherapy include the fo llowing: cough/productive 
cough, pneumonitis, ILD, dysphonia, A LT/AST increased, hepatiti s, diarrhea, abdominal pain, 
colitis, hypothyroidism, hyperthyr oidism, blood TSH increased, blood TSH decreased, adrenal 
insufficiency, hypophysitis/hypopitu itarism, type 1 diabetes me llitus, diabetes insipidus, blood 
creatinine increase d, dysuria, nephritis, r ash, pruritus, night  sweats, dermatitis myocarditis, 
pyrexia, peripheral edema, upper respiratory tract infections, pneumonia, oral candidiasis, dental 
and oral soft tissue infections, i nfluenza, myalg ia, myositis, polymyositis and infusion related 
reaction.  The following events have been seen with other checkpoint inhib itors (Naidoo et al 2015, 
Champiat et al 2016) and/or may pos sibly occur due to the mecha nism of action of the PD-1/PD-
L1 class or mAb therapeutics in general. 
 Potential imAEs including: 
o Pancreatitis  
o Other rare or less frequent events with a potential immune-medi ated aetiology, eg, 
pericarditis, sarcoidosis, uve itis, and other events involving the eye (eg, keratitis and 
optic neuritis), skin (eg, scleroderma and vitiligo), and haema tological (eg, haemolytic 
anaemia and immune thrombocytope nic purpura), rheumatological e vents 
(polymyalgia rheumatic and auto immune arthritis), neuropathy/ne uromuscular 
toxicities (eg, myasthenia grav is, Guillain Barre syndrome), va sculitis, non-infectious 
meningitis and non-infec tious encephalitis. 
 Hypersensitivity reactions including: 
o Anaphylaxis and allergic reaction 
o Cytokine release syndrome 
o Immune complex disease 
 Other infections 
 
Please refer to the current ver sion of the Investigator’s Broch ure (IB) for additional information 
regarding this drug.  11. ADVERSE EVENTS  
11.1. Definitions 
 11.1.1.  Adverse Event (AE): 
Any untoward medical occurrence in a subject or clinical trial participant which does not necessarily 
have a causal relationship with t he treatment. An adverse event  (AE) can therefore be any 
unfavorable and unintended sign ( including an abnormal finding) , symptom, or disease temporally 
associated with the use of an i nvestigational product, whether or not related to the investigational 
product.  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 62 of 79 An AE includes but is not limite d to any clinica lly significant  worsening of a subj ect’s pre-existing 
condition. An abnormal laboratory finding (including ECG findin g) that requires an action or 
intervention by the investigator, or a finding judged by the in vestigator to represent a change beyond 
the range of normal  physiologic fluctuation, should be reported  as an AE. 
 Adverse events may be treatment e mergent (i.e., occurring after  initial receipt of investigational 
product) or non-treatment-emerge nt. A non-treatment-emergent AE  is any new sign or symptom, 
disease, or other untoward medical event that begins after writ ten informed consent has been 
obtained but before the subject has  received inve stigational pr oduct.  
 Elective treatment or surgery or  preplanned treatment or surger y (that was scheduled prior to the 
subject being enrolled into the study) for a documented pre-exi sting condition, that did not worsen 
from baseline, is not considered an AE (serious or non-serious) . An untoward medical event 
occurring during the prescheduled elective procedure or routine ly scheduled treatment should be 
recorded as an AE or SAE.  11.1.2.  Serious Adverse Event (SAE): 
A serious adverse event is any adverse event that: 
 Results in death 
 Is life-threatening (defined as an event in which the subject w as at risk of death at the time 
of the event; it does not refer to an event which hypotheticall y might have caused death if it 
were more severe) 
 Requires inpatient hospitalizati on or prolongation  of existing hospitalization 
 Results in persistent or significant disability/incapacity 
 Is a congenital anom aly or birth defect 
 Is an important medical event (defined as a medical event(s) th at may not be immediately 
life-threatening or result in d eath or hospitalization but, bas ed upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention (e.g., medical, 
s u r g i c a l )  t o  p r e v e n t  o n e  o f  t h e  other serious outcomes listed i n the definition above). 
Examples of such events include, but are not limited to, intens ive treatment in an emergency 
room or at home for allergic bronchospasm; blood dyscrasias or convulsions not resulting in 
hospitalization; or the developm ent of drug dependency or drug abuse. 
 11.1.3.  Definition of Immune-Mediated Adverse Events (imAEs) 
Immune-related AEs are adverse events associated with the treat ment of patients with 
immunotherapy treatments that a ppear to be associated with the immune therapy’s mechanism of 
action. Based on these potential imAEs, AstraZeneca/Medimmune h as defined a list of specific 
adverse event terms (see AESIs be low) that are selected adverse  events that must be reported to 
Big Ten Cancer Research Consortiu m Administrative Headquarters (Big Ten CRC AHQ) 
within 24 hours from the time the site investig ator is aware of  such an occurre nce, regardless of 
whether or not the site investig ator considers the event to be related to study drug(s). See Section 
11.2 for reporting criteria.  11.1.4.  Definition of Adverse Events of Special Interest (AESI) 
Adverse events of special interest (AESIs) are events of scient ific and medical int erest specific to 
the further understanding of the  durvalumab safety profile and require close monitoring and rapid 
communication by the investigator t o the sponsor-investigator a nd Big Ten CRC AHQ. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 63 of 79 Durvalumab AESIs may be serio us or non-serious. The rapid repor ting of these AESIs allows 
ongoing analysis of these events in order to characterize and u nderstand them in association with 
the use of this inve stigational product.  Adverse events that are both an SAE and an AESI should 
be reported one time as an SAE only.  AESIs for durvalumab include: 
 Diarrhea/ Colitis and intestinal perforation 
 Pneumonitis/ ILD 
 Hepatitis/ transaminase increases 
 Endocrinopathies (i.e . events of hypophysitis/ hypopituitarism, adrenal insufficiency, 
hyper- and hypothyroidism and type  I diabetes mellitus) 
 Rash/ Dermatitis 
 Nephritis/ Blood creatinine increases 
 Pancreatitis/ serum lipase and amylase increases   
 Myocarditis 
 Myositis/ Polymyositis 
 Neuropathy/ neuromuscular toxic ity (e.g. Guillain-Barré, and my asthenia gravis) 
 Other inflammatory responses tha t are rare/ less frequent with a potential immune-
mediated etiology include, but are  not limited to, pericarditis , sarcoidosis, uveitis and other 
events involving the eye/skin, hema tological and rheumatologica l events, vasculitis, 
non-infectious meningitis and non- infectious encephalitis. 
 
11.1.4.1.  Pneumonitis  
Adverse events of pneumonitis are of interest for AstraZeneca/M edimmune, as pneumonitis has 
been reported with anti-PD-1 MAbs (Topalian et al, NEJM 2012). Initial work-up should include 
high-resolution CT scan, ruling out infection, and pulse oximet ry. Pulmonary consultation is 
highly recommended.   Guidelines for the management of subjects with immune-mediated adverse events including 
pneumonitis are outlin ed in Section 6.1.1. 
 11.1.4.2.  Hypersensitivity Reactions 
Hypersensitivity reactions as well as infusion-related reaction s have been reported with anti-PD-
L1 and anti-PD-1 therapy (Brahmer et al 2012). As with the admi nistration of any foreign protein 
and/or other biologic agents, reactions following the infusion of MAbs can be caused by various 
mechanisms, including acute ana phylactic (immunoglobulin E-medi ated) and anaphylactoid 
reactions against the MAb, and serum sickness. Acute allergic r eactions may occur, may be 
severe, and may result in death. Acute allergic reactions may i nclude hypotension, dyspnea, 
cyanosis, respiratory failure, urticaria, pruritus, angioedema,  hypotonia, arthralgia, 
bronchospasm, wheeze, cough, dizziness, fatigue, headache, hype rtension, myalgia, vomiting, 
and unresponsiveness.  Guidelines for management of subjects with hypersensitivity (in cluding anaphylactic reaction) 
and infusion-related reac tions are outlined in Section 6.1.1. 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 64 of 79 11.1.4.3.  Hepatic function abnormal ities (hepatotoxicity) 
Increased transaminases have been  reported during treatment wit h anti-PD-L1/anti-PD-1 
antibodies (Brahmer et al 2012). Inflammatory hep atitis has bee n reported in 3% to 9% of 
subjects treated with anti-C TLA-4 monoclonal antibodies (e.g., ipilimumab). The clinical 
manifestations of ipilimumab-tr eated subjects included general weakness, fatigue, nausea, 
and/or mild fever and increased  liver function tests such as AS T, ALT, alkaline phosphatase, 
and/or total bilirubin.  Hepatic function abnormality is defined as any increase in ALT or AST to greater than 3 × ULN 
and concurrent  increase in total bilirubin to be greater than 2 × ULN. Concurr ent findings are 
those that derive from a single blood draw or from separate blo od draws taken within 8 days of 
each other. Follow-up investigations and inquiries will be init iated promptly by the 
investigational site to determine whether the findings are repr oducible and/or whether there is 
objective evidence that clearl y supports causation by a disease  (e.g., cholelithiasis and bile duct 
obstruction with distended gallbladder) or an agent other than the investigational product. 
Guidelines for management of subjects with hepatic function abn ormality are outlined in Section 
6.1.1.  Cases where a subject shows an AST or ALT ≥3×ULN or total bilirubin ≥ 2×ULN may need to 
be reported as SAEs, these cases should be reported as SAEs if,  after evaluation, they meet the 
criteria for a Hy’s Law case or i f any of the individual liver test parameters fulfill any of the SAE 
criteria.  Criteria for Hy’s Law  (FDA Guidance 2009) 
 The drug causes hepatocellular injury, generally shown by a hig her incidence of 3-fold or 
greater elevations above the ULN of ALT or AST than the (non-he patotoxic) control drug 
or placebo  
 Among trial subjects showing such  aminotransferase elevations, often with 
aminotransferases much greater than 3 x ULN, one or more also s how elevation of serum 
total bilirubin to >2 x ULN, w ithout initial findings of choles tasis (elevated serum alkaline 
phosphatase)  
 No other reason can be found to explain the combination of incr eased aminotransferases and 
total bilirubin, such as viral hepatitis A, B, or C; pre-existi ng or acute liver disease; or another 
drug capable of causing the observed injury. 
 11.1.5.  Unexpected Adverse Event: 
An adverse event not mentioned in the Investigator's Brochure o r Prescribing Information or the 
specificity or severity of which is not consistent with the Inv estigator's Brochure or Prescribing 
Information, or is not included i n the informed consent documen t as a potential risk. 
 11.1.6.  Related Adverse Event 
There is a reasonable possibilit y the drug caused the adverse e xperience. 
 
Unrelated The Adverse Event is clearly not related to the investigational agent(s) 
Unlikely The Adverse Event is doubtfully related  to the investigational agent(s) 
Possible The Adverse Event may be related  to the investigational agent(s) 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 65 of 79 Probable The Adverse Event is  likely related to the investigational agent(s) 
Definite The Adverse Event is clearly related  to the investigational agent(s) 
 
11.2. Reporting 
 
11.2.1.  Adverse Events (AEs) 
Adverse events (AEs) will be recorded from the time of consent and for at least 90 days after 
treatment discontinuation, regardless of whether or not the eve nt(s) are considered related to trial 
medications. The descriptions a nd grading scales found in the r evised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4 will be utilized for AE reporting. A copy of the 
current CTCAE version can be downl oaded from the CTEP website a t http://cte p.cancer.gov.  
 During the course of the study all AEs should be proactively fo llowed up for each subject. The 
investigator is responsible for following all AEs until resolut ion, return to baseline status, or 
stabilization with the expectation that it will remain chronic,  even if this extends beyond study drug 
administration.  
11.2.2.  Serious Adverse Events (SAE)  
 
11.2.2.1.  Site Requirements for Reporting SAEs: 
Investigators and other site personnel must report all SAEs occ urring during the course of the 
study within one business day  of discovery of the event. This includes events both related a nd 
unrelated to the investigational product or to the study proced ure(s). The reporting period for 
SAEs is the period immediately following the time that written informed consent is obtained 
through 90 days after the last dose of durvalumab or until the initiation of alternative anticancer 
therapy.   The completed SAE Submission Form (see Documents/Info tab of th e EDC) must be sent 
electronically to SAFETY@hoosiercancer.org  at Big Ten Cancer Research Consortium 
(Big Ten CRC) Administrative Headquarters (AHQ) within one busi ness day of discovery 
of the event. The investigator is responsible f or informing the IRB and/or th e Regulatory 
Authority of the SAE as per local requirements. 
The original copy of the SAE Sub mission Form and the e-mail cor respondence must be kept 
within the study file at the study site. 
Follow-up information must be sent electronically to Big Ten CR C AHQ at 
SAFETY@hoosiercancer.org , using a new SAE Submission For m stating that this is a follow -
up to the previously reported SAE and giving the date of the or iginal report. Each re-occurrence, 
complication, or progression of t he original event should be re ported as a follow-up to that event 
regardless of when it occurs.   The follow-up informa tion should describe:  
 whether the event has resolved or continues,  
 if and how it was treated,  
 whether the subject continue d or withdrew fro m study participat ion. 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 66 of 79 11.2.3.  Big Ten CRC AHQ Requirements  for Reporting SAEs: 
 
11.2.3.1.  Big Ten CRC AHQ Reporting t o AstraZeneca/ MedImmune 
Big Ten CRC AHQ will submit all FDA reportable SAEs to AstraZen eca within one business 
day of receipt of the SAE Submission Form from the site. Big Ten C RC AHQ will submit a 
MedWatch Form to AstraZeneca  and will provide follow-up information as reasonably 
requested.  Serious adverse events  that do not require expedited reporting to the FDA still need t o be 
reported to AstraZeneca, preferabl y using the MedDRA coding lan guage for serious adverse 
events. This information should be  reported on a monthly basis and under no circumstance less 
frequently than quarterly. 
 
Send SAE report and accompanying cover page by way of email to AstraZeneca’s 
designated mailbox:    AEMailboxClinicalTrialTCS@astrazeneca.com 
 
11.2.3.2.  Big Ten CRC AHQ Reporting to the F ood and Drug Administration ( FDA) 
Big Ten CRC AHQ will manage the Investigational New Drug Applic ation (IND) associated 
with this protocol on behalf of Shadia Jalal, M.D., Sponsor-inv estigator. Big Ten CRC AHQ 
will cross-reference this submission according to local regulat ions to the AstraZeneca 
Investigational Compound Number (IND, CSA, etc.) at the time of  submission. Additionally, 
Big Ten CRC AHQ will submit a copy of these reports to AstraZen eca at the time of submission 
to FDA.   Big Ten CRC AHQ will be responsible for all communication with the FDA including but not 
limited to 7 and 15 Day Reports, as well as an Annual Progress Report. Big Ten CRC AHQ will 
report to the FDA, regardless of the site of occurrence, any AE  that is serious, unexpected, and 
reasonably related (i.e., possibl e, probably, definite) to the study treatment. The sponsor-
investigator will review these reports and determine if any rev isions are needed to the protocol 
or consent.  7-Day Reports : 
 Big Ten CRC AHQ will report unexp ected fatal or life-threatenin g events associated with 
the use of the study treatment w ill be reported to the FDA. 
 Big Ten CRC AHQ will report these events either by fax or by ph one as soon as possible 
but in no event later than 7 calendar days after the initial re ceipt of the information regarding 
the event. The fax should be sent  to the FDA project manager as signed to the IND. A 
comprehensive written report will be submitted as an amendment to the IND within an 
additional 8 days (15 cal endar days, total). 
15-Day Reports : 
 Big Ten CRC AHQ will submit all oth er serious unexpected events  associated with the use 
of the study treatment to FDA as an amendment to the IND as soo n as possible but in no 
event later than 15 calendar days  after initial receipt of the information regarding the event.  
 
* A cover page  should accompany the MedWatch f orm indicating the following: 
 “Notification from an Inv estigator Sponsored Study” 
 The investigator IND number assigned by the FDA 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 67 of 79  The investigator’s name and address 
 The trial name/title and AstraZen eca ISS reference number (ESR- 14-10654) 
 * Sponsor must also indicate, either in the SAE report or in the cover page, the causality of 
events in relation to all study medications and if the SAE is r elated to disease progression, as 
determined by the prin cipal investigator. 
 Annual Progress Reports 
 Big Ten CRC AHQ will submit an annua l progress report within 60  days of the anniversary 
of the date that the IND went into effect. 
 
11.2.4.  Other events requiring immediate reporting 
 
11.2.4.1.  Requirements for Reporting Overdose 
An overdose is defined as a subject receiving a dose of durvalu mab in excess of that specified 
in the Investigator’s Brochure , unless otherwise specified in t his protocol. 
 Any overdose of a study subject with durvalumab, with or withou t associated AEs/SAEs, is 
required to be reported to Big Ten CRC AHQ within 24 hours of k nowledge of the event. Big 
Ten CRC AHQ will report the event to AstraZeneca/MedImmune Pati ent Safety or designee 
within 24 hours using the designated Safety e-mailbox. If the o verdose results in an AE, the 
AE must also be recorded as an AE. Overdose does not automatica lly make an AE serious, but 
if the consequences of the overdos e are serious, for example de ath or hospitalization, the event 
is serious and must be recorded and reported as an SAE. There i s currently no specific 
treatment in the event of  an overdose of durvalumab.  
 The investigator will use clin ical judgment t o treat any overdo se. 
 
11.2.4.2.  Requirements for Reporting H epatic function abnormality 
Hepatic function abnormality ( as defined in Section 11.1.4.3) i n a study subject, with or 
without associated clinical manif estations, is required to be r eported as “hepatic function 
abnormal” within 24 hours of knowledge of the event to Big Ten CRC AHQ, unless a 
definitive underlying diagnosis for the abnormality (e.g., chol elithiasis or bile duct 
obstruction) that is unrelated to investigational product has b een confirmed. Big Ten CRC 
AHQ will report the event to AstraZeneca/MedImmune Patient Safe ty or designee within 24 
hours using the designa ted Safety e-mailbox. 
 If the definitive underlying diagnosis for the abnormality has been established and is 
unrelated to investigational pr oduct, the decision to continue dosing of the study subject 
will be based on the clinical judgmen t of the site investigator . 
 If no definitive underlying diagnosis for the abnormality is es tablished, dosing of the study 
subject must be interrupted immed iately. Follow-up investigatio ns and inquiries must be 
initiated by the investigati onal site without delay. 
 Each reported event of hepatic  function abnormality will be fol lowed by the site investigator 
and evaluated by the sponsor-inv estigator and AstraZeneca/MedIm mune.  
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 68 of 79 11.2.4.3.  Requirements for Reporting Pregnancy 
Pregnancy itself, or pregnancy of a subject’s partner, is not r egarded as an adverse event unless 
there is a suspicion that the i nvestigational product under stu dy may have interfered with the 
effectiveness of a contraceptive medication. Congenital abnorma lities/birth defects and 
spontaneous miscarriages should be reported and handled as SAEs . Elective abortions without 
complications should not be handled as AEs.  The outcome of any conception occurring from 
the date of the first dose until 90 days after the last dose (s pontaneous miscarriage, elective 
termination, ectopic pregnancy, normal birth, or congenital abn ormality) should be followed 
up and documented even if the subj ect was withdrawn from the st udy drug.   
 Pregnancy in a female subject who has received investigational product is required to be 
reported within 24 hours of kn owledge of the event  to Big Ten CRC AHQ on the Pregnancy 
Report form (See Documents/Info tab of the EDC). Big Ten CRC AH Q will report the event 
to AstraZeneca/MedImmune Patient Safety or designee within 24 h ours using the designated 
Safety e-mailbox.  Subjects who become pregnant during the study period must not r eceive additional doses of 
investigational product but will not be withdrawn from the stud y. The pregnancy will be 
followed for outcome of the mother and child (including any pre mature terminations) and 
should be reported to Big Ten CRC AHQ after outcome. Big Ten CR C AHQ will report the 
event to AstraZeneca/MedImmune Patient Safety or designee withi n 24 hours using the 
designated Safety e-mailbox.  Male subjects should refrain from fathering a child or donating  sperm during the study and for 
3 months following the last dose.   Should the investigator become awa re of a pregnancy in the part ner of a male study subject 
who has received investigationa l product this should be reporte d within 24 hours of 
knowledge of the event  to Big Ten CRC AHQ on the Pregnancy Report form (See 
Documents/Info tab of the EDC). The site investigator will ende avor to collect follow-up 
information on such pregnancies pr ovided the partner of the stu dy subject provides consent. 
 
11.3. IND Safety Reports Unrelated to This Trial 
IND safety reports not occurring on this trial but involving th e study intervention (outside SAEs) 
received from outside sources will be forwarded to participatin g sites for submission to their 
Institutional Review Boards per their guidelines. The sponsor-i nvestigator will review these reports 
and determine if any revisions are  needed to the protocol or co nsent. 
  12. STATISTICAL CONSIDERATIONS 
12.1. General Considerations 
Statistical analysis of this st udy will be the responsibility o f Biostatistics and Data Management 
Core at Indiana University Melvi n and Bren Simon Cancer Center (IUSCC). Parameter estimates 
and relevant summary statistics will be reported where appropri ate. For continuous variables, 
summary statistics will include number of subjects, mean, media n, standard deviation, minimum 
and maximum. Categorical endpoints will be summarized using num ber of subjects, frequency, and 
percentages. Missing data will not be imputed. Data analysis wi ll be performed in SAS Version 9.4. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 69 of 79  
Additional exploratory analyses  of the data will be conducted a s deemed appropriate. Changes from 
this analysis plan will not require an amendment to the protoco l unless it changes a significant 
feature of t he protocol. 
 12.2. Study Design 
This is an open label single-ar m single-stage phase II trial.  
 12.3. Definition of Primary Endpoint 
- Relapse free survival: Time from the date of surgery until the criteria for disease relapse 
is met or death occurs. 
- One year relapse free survival: Subject is alive and relapse fr ee at one year post-surgery.   
 12.4. Definitions of Secondary Endpoints 
- Toxicity and tolerability: The o ccurrence and rate of any AEs, SAEs, AESIs, or imAEs 
while being on study drug and up to 30 days of receiving the fi nal dose of the study drug. 
 12.5. Definitions of Correlative Endpoints 
- Programmed death ligand -1 expres sion at cellular level in the specimen of residual tissue 
obtained at the tim e of esophagectomy  
- Assessment of tumor infiltrating lymphocytes by histologic anal ysis within the tumor 
and in surrounding connective tissue 
- Immunoscore (based on numeration of lymphocyte populations – CD 3/CD45RO, 
CD3/CD8, CD8/CD45RO) within the  tumor and in surrounding connec tive tissue 
- Changes in the circulating tumor  cells collected at baseline, a t 3 months, and a t the time 
of disease recurrence (duri ng treatment or follow up). 
 
12.6. Sample Size/Accrual/Study Dur ation/Replacement Rules  
Historical outcomes of  patients who receive chemoradiotherapy f ollowed by surgic al resection and 
are noted to have persistent disease at the time of surgery are  poor with 50% of them recurring in 
the first year (34). We expect dur valumab to impr ove the relaps e free survival at 1 year rate by 25%. 
The null hypothesis is that 1 year RFS with postoperative adjuv ant durvalumab therapy in patients 
with persistent esophageal cance r following neoadjuvant chemora diotherapy and esophagectomy is 
50% or less. Alternative hypothesi s is that 1 year RFS with pos toperative adjuvant durvalumab 
therapy in patients with persi stent esophageal cancer following  neoadjuvant chemoradiotherapy and 
esophagectomy is 75% or greater. With a maximum acceptable type  I error (the probability of 
concluding that the drug is effective when it is actually not e ffective) of 0.05, and acceptable type 
II error (the probability of concluding that the drug is not ef fective when it is actually effective) of 
0.20, the calculated sample size is 23 evaluable patients. If t he total number of patients free of relapse 
at 1 year is less than or equal to 15, the drug would not be co nsidered for further study. Up to 26 
will be enrolled to allow for 10% unevaluable for efficacy. Sub jects who receive less than 6 months 
of durvalumab for reasons unrel ated to disease progression or t oxicity will be replaced. Estimated 
accrual period is 18 months; follow up period of 12 months.  To  improve accuracy for estimating 
the primary endpoint (1 year RFS) with a 95% confidence interva l, an additional 11-16 patients 
beyond the initial planned 23 evaluable will be enrolled for a target of 39 enrolled and at least 34 
patients evaluable for 1 year RFS (to allow for approximately 1 0% unevaluable).  With n=34 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 70 of 79 evaluable, if the 1 year RFS is 75%, a 95% two-sided confidence  interval will have a half-width of 
15% (using normal-approximation).  12.7. Criteria for Stopping the Study 
Safety: The first six subjects treated with at least one dose o f study drug will be observed for a 
minimum of 60 days. During the 6th subject’s 60-day observation pe riod, further accrual will be 
halted to evaluate "un acceptable toxicities  warranting early cl osure of the trial" defined as: 
1) Any definitive durvalumab-relate d death. A durvalumab-related d eath will be continuously 
monitored throughout the trial and the trial will be suspended for re-evaluation whenever such 
an event is confirmed. 
2) Any unexpected and previously unre ported grade 4 toxicities def initely related to durvalumab. 
 If such events are observed in one subject, the DSMB will discu ss and provide recommendations to 
the sponsor-investigator. If such events are observed in two or  more subjects, the trial will be 
suspended for re-evaluation.  Pneumonitis of grade 3 and 4 will be continuously monitored. An  overall rate of 20% or above 
would be considered unacceptable. If the probability of the gra de 3/4 pneumonitis rate being less 
than 20% drops below 0.1, the trial will be suspended for re-ev aluation. 
 12.8. Analysis Datasets 
 
Population Definition 
Enrolled This will comprise all patients who meet the eligibili ty 
criteria and are regi stered onto the study.  
Efficacy Evaluable  This will comprise all patients who receive  at least one dose 
of trial drug and either undergo at least one post-baseline assessment or die before any evaluation.     
Safety This will comprise all patients that receive at least on e dose 
of durvalumab 
 
12.9. Subject Characteristics and sign ificant protocol violations 
Subject demographics and subject  baseline clinical  characterist ics will be listed and summarized 
for all subjects enrolled, including age, gender, and race by p hase. Counts, means, medians, 
standard deviation, minimum and maximum values will be presente d. Significant protocol 
violations will be listed.  12.10.  Concomitant Medication 
Concomitant medication use will be tabulated. 
  12.11.  Disposition 
Subject disposition will be tabulated and will show the number of subjects enrolled, and the 
number of subjects completing the  study. All reasons for discon tinuation will  be listed and 
summarized.  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 71 of 79 12.12.  Analysis Plan for Primary Objectives/Aims 
In the efficacy evaluable popula tion, our primary analysis will  be to estimate RPS at 1 year with a 
95% confidence interval.   Kaplan-Meier curve w ill also be estimated for the relapse free survival 
curve.   12.13.  Analysis Plan for Secondary Objectives/Aims 
In the safety population, toxicity will be summarized by rates and 95% confidence intervals. 
Toxicity analysis will be carried out after 30 days following r eceipt of the final dose of the study 
drug by the last study patient. We will tabulate AEs, AESIs, an d imAEs, both with and without 
considering drug attribution.  12.14.  Analysis Plan for Correlative/Exploratory Objectives 
In the efficacy evaluable populat ion, change in PD-L1 expressio n from diagnosis to surgery will 
be assessed using a paired t-tes t or Wilcoxon signed-rank test as appropriate. 
 Changes in PD-L1 expression, Immunoscore values, and changes in  CTCs over time will be 
correlated with 1 year RFS using t wo-sample tests or Wilcoxon r ank sum tests as appropriate.  We 
will also explore time to event  analyses with RFS using log-ran k tests. 
 Differential gene expression will be performed in R using DESeq 2. These files will be 
downloaded and uploaded to Partek Genomics Suite v6.6 for visua lization. Pathway analysis will 
be performed using Ingenuity Pathw ay Analysis.  CIBERSORT analy sis to identify the immune 
cell make up based on gene expression will also be performed.   13. TRIAL MANAGEMENT 
13.1 Data and Safety Monitoring Plan (DSMP) 
The study will be conducted in accordance with Indiana Universi ty Melvin and Bren Simon 
Cancer Center Institutional Da ta and Safety Monitoring Plan (DS MP) for High Risk Phase II 
Trials.  Big Ten CRC AHQ facilitated overs ight activities for High Risk Phase II Trials include : 
 Review and processing of all adverse events requiring expedited  reporting as defined in the 
protocol 
 Notify participating sites of adve rse events requiring expedite d reporting  
 Provide trial accrual progress, s afety information, and data su mmary reports to the sponsor- 
investigator, including a weekl y update of aggregate AE data. F or any increase in frequency 
of grade 3 or above adverse even ts (above the rate reported in the Investigator Brochure or 
package insert), the sponsor i nvestigator will notify Big Ten C RC AHQ who will notify the 
DSMC Chair and Compliance Office r immediately. The notification  will include the 
incidence of study adverse even ts, grades, and attributions, as  well as investigator statements 
regarding comparison with risks  per the IB/ package insert. 
 Coordinate monthly  (Phase II) meetings which will include representation from eac h 
accruing site. 
o These meetings should include r eview of data, the number of sub jects and significant 
toxicities as described in the  protocol. Big Ten CRC AHQ should  maintain meeting 
minutes and attendance for submission to the DSMC. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 72 of 79  Conduct the trial acro ss all participating s ites in accordance with the requirements set forth 
in the IUSCC DSMP. 
 
13.1.1 Big Ten CRC AHQ Study-Specifi c Data and Safety Monitorin g Board (DSMB) 
This study will have a study-specific Data and Safety Monitorin g Board (DSMB) managed 
through Big Ten CRC AHQ.  The Bi g Ten CRC AHQ DSMB will review and monitor study 
progress, toxicity, safety, and othe r data from this trial. The  board is chaired by an independent 
medical oncologist or another qua lified individual external to this trial.   
 
The DSMB will meet semi-annually during the active treatment an d safety follow-up portion of 
the trial to review the following:  
 Monthly Summary Reports 
 Reports of the following, if not a lready included in the Monthl y Summary Report: 
o Adverse event summary (incl uding serious adverse events) 
o Study accrual patterns 
o Protocol deviations 
 Audit and/or monitoring re sults, if applicable 
 Data related to stopping rul es described in study design 
 Big Ten CRC AHQ meeting minutes/ attendance 
 
After all information has been r eviewed, the Big Ten CRC AHQ DS MB will provide a 
determination to the sponsor-inv estigator.  The report may indi cate one or more of the 
following decisions: 
 Continuation of the trial without change 
 Continuation of trial with modi fications as outlined by the boa rd 
 Immediate suspension of trial for  safety reasons with recommend ed plan of follow-up to 
minimize subject harm 
 Termination of trial 
 Big Ten CRC AHQ will distribute th e official DSMB determination s to the site investigators/ 
participating sites for sub mission to applicable oversight bodi es, including their respective 
IRBs, according to the local policies and procedures.   Documentation of DSMB outcomes will also be provided to MedImmu ne and the IUSCC DSMC 
Chair via the DSMC Compliance Auditor (see next section).   
 
Investigators will conduct continuous review of data and subjec t safety.  At any time during the 
conduct of the trial, if it is t he opinion of the sponsor-inves tigator that the risks (or benefits) to the 
subject warrant earl y closure of the st udy, this decision shoul d be made in writing to the IUSCC 
DSMC Chair and Compliance Office r. Alternatively, the IUSCC DSM C may initiate suspension 
or early closure of the study at any time based on its review o f the DSMB study reports. 
 
13.1.2 IUSCC Data and Safety Monit oring Committee (DSMC) Oversi ght 
The IUSCC DSMC retains authority  over this study and may reques t additional actions based on 
the study’s DSMB reports; howev er, the IUSCC DSMC defers to the  study-specific DSMB for 
routine review and decision m aking per the IUSCC DSMP.   
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 73 of 79  
The IUSCC DSMC will review the s tudy-specific DSMB reports semi -annually.  
 
When the study is due for DSMC re view, the DSMC Compliance Audi tor will request the most 
recent study summary r eports, Big Ten CRC AHQ monthly meeting m inutes, and DSMB 
Outcome Letter(s).  The DSMC Chai r will administratively review  these documents and may 
request additional reports. If  no issues were found or if issue s have been resolved, the DSMC 
Chair may accept the DSMB’s de termination and allow the study t o continue without  doing a full 
DSMC review. For DSMB suspensi ons or other issues of concern, t he DSMC Chair will review at 
the DSMC Monthly meeting and may r efer to the DSMC Full Meeting  as needed for further 
discussion.  
 
Trials managed by Big Ten CRC A HQ are not routinely audited or monitored by IUSCC; 
however, the IUSCC DSMC retains t he right to audit Big Ten CRC trials on a for cause basis.  
 
IND Annual Reports  
For trials with an IND held loca lly by the IU principal investi gator or university, the IND Annual 
Report will be prepared and subm itted to the IUSCC Compliance O fficer. This report will be 
reviewed by the DSMC at the  time of FDA submission.  
 
13.2 Data Quality Oversight Activities 
Remote validation of the EDC sys tem data will be completed on a  continual basis throughout the 
life cycle of the study. Automated edit check listings will be used to generate queries in the EDC 
system and transmitted to the site to address in a timely fashi on. Corrections will be made by the 
study site personnel.   13.2.1 Data Monitoring Monitoring will be conducted in acc ordance with the IUSCC DSMP for High Risk Phase II Trials.  
Monitoring visits to the trial sites may be made periodically d uring the trial to e nsure key aspects 
of the protocol are followed. For  cause visits may occur as nec essary. Selected source documents 
will be reviewed for verification o f agreement with data entere d into the EDC system.  It is 
important for the site investigat or and their relevant personne l to be available for a sufficient 
amount of time during the monitori ng visits or audit, if applic able. The site investigator and 
institution guarantee access to s ource documents by Big Ten CRC  AHQ or its designee. 
 The trial sites may also be subject to quality assurance audit by MedImmune  or its designee as well 
as inspection by appropriate  regulatory agencies. 
 
13.3 Compliance with Trial Registr ation and Results Posting Req uirements 
Under the terms of the Food and Drug Administration Modernizati on Act (FDAMA) a nd the Food 
and Drug Administration Amendments Act (FDAAA), the sponsor-inv estigator of the trial is solely 
responsible for determining whet her the trial and its results a re subject to the requirements for 
submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov . All results of primary 
and secondary objectives must be posted to CT.gov within a year  of completion. The sponsor-
investigator has delegated res ponsibility to Bi g Ten CRC AHQ fo r registering the trial and posting 
the results on clinicaltrials.gov.  Information posted will allo w subjects to identify potentially 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 74 of 79 appropriate trials for their di sease conditions and pursue part icipation by calling a central contact 
number for further informati on on appropriate trial locations a nd study site contact information. 
 
14. DATA HANDLING AND RECORD KEEPING 
14.1 Case Report Forms and Submission 
This study will utilize electronic case report forms (eCRFs) in  an electronic data capture (eDC) 
system. The eDC system will be c ompliant with Good Clinical Pra ctices and Federal Rules and 
Regulations, to include 21 CFR Part 11.   Generally, clinical data will be electronically captured in the  eDC and correlative results will be 
captured in the eDC or other secure database(s). If procedures on the study calendar are performed 
for standard of care, at minimum, that data will be captured in  the source document. Select standard 
of care data will also be captured in the eDC, according to stu dy-specific objectives. Please see 
guidelines in the Documents/Inf o tab of the EDC for further det ails.  
 The completed dataset is housed at Big Ten CRC AHQ and is the s ole property of the sponsor-
investigator’s institution. It should not be made available in any form to third parties, except for 
authorized representatives of appropriate Health/Regulatory Aut horities, without written permission 
from the sponsor-inves tigator and Big Ten CRC AHQ. After the in itial publication, the complete 
data set will be available to a ll Big Ten CRC institutions. 
 14.2 Record Retention 
To enable evaluations and/or aud its from Health Authorities/Big  Ten CRC AHQ, the investigator 
agrees to keep records, including the identity of all participa ting subjects (sufficient information to 
link records; e.g., hospi tal records), all ori ginal signed info rmed consent forms, copies of all source 
documents, and detailed records of drug disposition. To comply with international regulations, the 
records should be retained by the  investigator in compliance wi th regulations. 
 During data entry, range and mis sing data checks will be perfor med on-line. The checks to be 
performed will be documented in the Data Monitoring Plan for th e study. A summary report (QC 
Report) of these checks together with any queries resulting fro m manual review of the eCRFs will 
be generated for each site and transmitted to the site and the site monitor. Corrections will be made 
by the study site personn el. This will be done on an ongoing ba sis. 
 14.3 Confidentiality 
There is a slight risk of loss of confidentiality of subject in formation. All records identifying the 
subject will be kept confidentia l and, to the extent permitted by the applicable laws and/or 
regulations, will  not be made publicly available.  
 Information collected will be mai ntained on secure, password pr otected electronic systems. Paper 
files that contain personal information will be kept in locked and secure locations only accessible to 
the study team. Samples that are collected will be identified b y a subject study number assigned at 
the time of registration to the trial. Any material issued to c ollaborating researchers will be 
anonymized and only identified by the subject study number. 
 Subjects will be informed in writing that some organizations in cluding the sponsor-investigator and 
his/her research associates, Big Ten CRC AHQ, MedImmune, IRB, o r government agencies, like 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 75 of 79 the FDA, may inspect their medical records to verify the inform ation collected, and that all personal 
information made available for inspection will be handled in st rictest confidence and in accordance 
with local data protection laws.  If the results of the  study are published, t he subject’s identi ty will remain confidential. 
 
14.4 Changes to the Protocol and Informed Consent 
Study procedures will not be cha nged without the mutual agreeme nt of the sponsor-investigator, 
Big Ten CRC AHQ, and MedImmune.  If it is necessary for the study protocol to be amended, the am endment or a new version of the study 
protocol (amended protocol) wi ll be generated by Big Ten CRC AH Q and must be approved by the 
Sponsor-Investigator and MedImmune in addition to each site’s I RB, and if applicable, also the 
local regulatory authority. Local r equirements mu st be followed . 
 If a protocol amendment requires a change to the informed conse nt form sites must notify their local 
IRB. Approval of the revised inf ormed consent form by the local  IRB is required before the revised 
form is used.   The local investigator is respons ible for the distribution of a mended documents to his or her IRB, 
and to the staff at his or her center. The distribution of thes e documents to the regulatory authority 
will be handled according to local practice.  MedImmune’s willingness to suppl y study drug is predicated upon  the review of the protocol. Big 
Ten CRC AHQ agrees to provide written notice to MedImmune of an y modifications to the protocol 
or informed consent.  15 ETHICS 
15.1 Ethics Review 
The final study protocol, includ ing the final version of the in formed consent form, must be approved 
or given a favorable opinion in writing by an IRB. The local in vestigator must submit written 
approval to the Big Ten CRC AHQ office before he or she can enr oll any subject into the study.  
 The local investigator is responsible for informing the IRB of any amendment to the protocol in 
accordance with local requirements. In addition, the IRB must a pprove all advertising used to recruit 
subjects for the study. The prot ocol must be re-approved by the  IRB at least annually, as local 
regulations require.   Progress reports and notifications of serious adverse events wi ll be provided to the IRB according 
to local regulati ons and guidelines. 
 The investigator is also respons ible for providing the IRB with  reports of any serious adverse events 
from any other study conducted w ith the investigational product , according to local policies. 
MedImmune will provide this information to the sponsor-investig ator. These reports will be 
reviewed by the sponsor-investigator and will be forwarded to p articipating sites every 2 weeks for 
submission to their Institutional Review Boards per their guide lines.  
 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 76 of 79 15.2 Ethical Conduct of the Study 
The study will be performed in acco rdance with ethical principl es originating from the Declaration 
of Helsinki, which are consisten t with ICH Good Clinical Practi ce, and applicable federal (including 
21 CFR parts 56 & 50), st ate, or local laws.  
 15.3 Informed Consent Process 
The investigator will ensure the subject is given full and adeq uate oral and written information about 
the nature, purpose, possible ri sks and benefits of the study. Subjects must also be notified they are 
free to discontinue from the study at any time. The subject sho uld be given the opportunity to ask 
questions and allowed time to con sider the information provided . 
 The subject’s signed and dated informed consent must be obtaine d before conducting any procedure 
specifically for the study. The i nvestigator must store the ori ginal, signed written informed consent 
form. A copy of the informed cons ent form must be given to the subject. 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 77 of 79 16 REFERENCES  
 
1. American Cancer Society: Cancer Facts and Figures 2015: Amer ican Cancer Society; 2015 
[cited 2015 07/01/2015]. 
2. SEER Stat Fact Sheets: Esopha geal Cancer: National Cancer In stitute; 2015 [cited 2015 
07/01/2015]. 
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. 
Signatures of mutational processe s in human cancer. Nature. 201 3;500(7463):415-21. 
4. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van  Berge Henegouwen MI, 
Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophag eal or junctional cancer. The 
New England journal of med icine. 2012;366(22):2074-84. 
5. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Va itkevicius V, et al. 
Combined chemotherapy and radioth erapy compared with radiothera py alone in patients with 
cancer of the esophagus. The New England journal of medicine. 1 992;326(24):1593-8. 
6. Disis ML. Immune regulation of  cancer. Journal of clinical o ncology : official journal of 
the American Society of C linical Oncology. 2010;28(29):4531-8. 
7. Al-Shibli KI, Donnem T, Al-S aad S, Persson M, Bremnes RM, Bu sund LT. Prognostic 
effect of epithelial and strom al lymphocyte infiltration in non -small cell lung can cer. Clinical 
cancer research : an official jour nal of the Ame rican Associati on for Cancer Research. 
2008;14(16):5220-7. 
8. Deschoolmeester V, Baay M, Van M arck E, Weyler J, Vermeulen P, Lardon F, et al. 
Tumor infiltrating lymphocytes: an intriguing player in the sur vival of colorectal cancer patients. 
BMC immunology. 2010;11:19. 
9. Diez M, Pollan M, Enriquez JM, Dominguez P, Santana A, Tobar uela E, et al. 
Histopathologic prognostic score i n colorectal adenocarcinomas.  Anticancer research. 
1998;18(1B):689-94. 
10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B,  Lagorce-Pages C, et al. 
Type, density, and location of imm une cells within human colore ctal tumors predict clinical 
outcome. Science. 2006;313(5795):1960-4. 
11. Hiraoka N. Tumor-infiltrati ng lymphocytes and hepatocellula r carcinoma: molecular 
biology. International journal  of clinical oncology. 2010;15(6) :544-51. 
12. Leffers N, Gooden MJ, de Jong R A, Hoogeboom BN, ten Hoor KA , Hollema H, et al. 
Prognostic significance of tumor- infiltrating T-lymphocytes in primary and metastatic lesions of 
advanced stage ovarian cancer. Cancer immunology, immunotherapy  : CII. 2009;58(3):449-59. 
13. Talmadge JE, Donkor M, Scholar  E. Inflammator y cell infiltr ation of tumors: Jekyll or 
Hyde. Cancer metastasis re views. 2007;26(3-4):373-400. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 78 of 79 14. Hodi FS, Dranoff G. The biolog ic importance of tumor-infilt rating lymphocytes. Journal of 
cutaneous pathology. 2010;37 Suppl 1:48-53. 
15. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawara da Y, et al. CD4+ and 
CD8+ T cells cooperate to improve  prognosis of patients with es ophageal squamous cell 
carcinoma. Cancer research. 2003;63(7):1555-9. 
16. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in toler ance and autoimmunity. 
Immunological rev iews. 2010;236:219-42. 
17. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1  and SHP-2 associate with 
immunoreceptor tyrosine-based s witch motif of p rogrammed death 1 upon primary human T cell 
stimulation, but only receptor lig ation prevents T cell activat ion. Journal of immunology. 
2004;173(2):945-54. 
18. Riley JL. PD-1 signaling in pr imary T cells. Immunological reviews. 2009;229(1):114-25. 
19. Sheppard KA, Fitz LJ, Lee JM , Benander C, George JA, Wooter s J, et al. PD-1 inhibits T-
cell receptor induced phosphorylation of the ZAP70/CD3zeta sign alosome and downstream 
signaling to PKCtheta. FEBS letters. 2004;574(1-3):37-41. 
20. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its liga nds in tolerance and 
immunity. Annual review of immunology. 2008;26:677-704. 
21. Kinter AL, Godbout EJ, McNall y JP, Sereti I, Roby GA, O'She a MA, et al. The common 
gamma-chain cytokines IL-2, I L-7, IL-15, and IL-21 induce the e xpression of programmed death-
1 and its ligands. Journal of  immunology. 2008;181(10):6738-46.  
22. Dong H, Strome SE, Salomao DR , Tamura H, Hirano F, Flies DB , et al. Tumor-associated 
B7-H1 promotes T-cell apoptosis: a potential mechanism of immun e evasion. Nature medicine. 
2002;8(8):793-800. 
23. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et  al. PD-1 is a regulator of 
NY-ESO-1-specific CD8+ T cell ex pansion in melanoma patients. J ournal of immunology. 
2009;182(9):5240-9. 
24. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR,  et al. Blockade of 
programmed death-1 ligands on dendr itic cells enhances T cell a ctivation and cytokine production. 
Journal of immunology. 2003;170(3):1257-66. 
25. Brahmer JR, Tykodi SS, Chow L Q, Hwu WJ, Topalian SL, Hwu P,  et al. Safety and 
activity of anti-PD-L1 antibody in p atients with advanced cance r. The New England journal of 
medicine. 2012;366(26):2455-65. 
26. Ibrahim R, Stewart R, Shalabi  A. PD-L1 blockade for cancer treatment: MEDI4736. 
Seminars in oncology. 2015;42(3):474-83. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-ESO14-012 
09OCT2019  Confidential  Page 79 of 79 27. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, et al. Preliminary 
data from a multi-arm expans ion study of MEDI4736, an anti-PD-L 1 antibody. ASCO Meeting 
Abstracts. 2014;32(15_suppl):3002. 
28. Zingg U, Montani M, Frey DM, D irnhofer S, Went P, Oertli D.  Influence of neoadjuvant 
radio-chemotherapy on tumor-infilt rating lymphocytes in squamou s esophageal cancer. European 
journal of surgical oncology : the  journal of the European Soci ety of Surgical Oncology and the 
British Association of Surgical Oncology. 2009;35(12):1268-72. 
29. Ibrahim EM, Al-Foheidi ME, A l-Mansour MM, Kazkaz GA. The pr ognostic value of 
tumor-infiltrating lymphocytes in triple-negative breast cancer : a meta-analysis. Breast cancer 
research and treatment. 2014;148(3):467-76. 
30. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing v ersus body size-based 
dosing of monoclonal antibodies in adult clinical trials. J Cli n Pharmacol. 2009;49(9):1012-24. 
31. Velcheti V, Schalper KA, Car vajal DE, Anagnostou VK, Syrigo s KN, Sznol M, et al. 
Programmed death ligand-1 expre ssion in non-small cell lung can cer. Laboratory investigation; a 
journal of technical met hods and pathology. 2014;94(1):107-16. 
32. Klintrup K, Makinen JM, Ka uppila S, Vare PO, Melkko J, Tuom inen H, et al. 
Inflammation and prognosis in color ectal cancer. European journ al of cancer. 2005;41(17):2645-
54. 
33. Galon J, Mlecnik B, Bindea G , Angell HK, Berger A, Lagorce C, et al. Towards the 
introduction of the 'Immunoscore ' in the classification of mali gnant tumours. The Journal of 
pathology. 2014;232(2):199-209. 
34. Shapiro J, van Lanschot JJ, H ulshof MC, van Hagen P, van Be rge Henegouwen MI, 
Wijnhoven BP, et al. Neoadjuvant  chemoradiotherapy plus surgery  versus surgery alone for 
oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The 
Lancet Oncology. 2015;16(9):1090-8.  